Veradigm (MDRX) 10-Q 8 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 02, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	1,124,804
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		177,952,607

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 135,003	$ 155,839
Restricted cash	8,769	6,659
Accounts receivable, net of allowance of $44,652 and $37,735 as of March 31, 2018 and December 31, 2017, respectively	495,695	567,873
Contract assets	45,068	0
Prepaid expenses and other current assets	130,051	115,463
Assets of disposal group held for sale	96,478	0
Total current assets	911,064	845,834
Fixed assets, net	164,878	165,603
Software development costs, net	235,845	222,189
Intangible assets, net	827,059	826,872
Goodwill	2,051,437	2,004,953
Deferred taxes, net	4,888	4,574
Contract assets - long-term	40,486	0
Other assets	129,610	148,849
Assets attributable to discontinued operations	4,945	11,276
Total assets	4,370,212	4,230,150
Current liabilities:
Accounts payable	101,818	97,583
Accrued expenses	102,028	85,915
Accrued compensation and benefits	82,141	99,632
Deferred revenue	540,289	546,830
Current maturities of long-term debt	19,503	27,687
Current maturities of non-recourse long-term debt - Netsmart	2,760	2,755
Current maturities of capital lease obligations	9,753	7,865
Liabilities of disposal group held for sale	31,048	0
Total current liabilities	889,340	868,267
Long-term debt	1,064,305	906,725
Non-recourse long-term debt - Netsmart	624,872	625,193
Long-term capital lease obligations	8,152	7,105
Deferred revenue	25,876	24,047
Deferred taxes, net	117,061	93,643
Other liabilities	72,526	92,205
Liabilities attributable to discontinued operations	14,276	21,358
Total liabilities	2,816,408	2,638,543
Redeemable convertible non-controlling interest - Netsmart	443,684	431,535
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of March 31, 2018 and December 31, 2017	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of March 31, 2018 and December 31, 2017; 270,601 and 177,953 shares issued and outstanding as of March 31, 2018, respectively; 269,335 and 180,832 shares issued and outstanding as of December 31, 2017, respectively	2,706	2,693
Treasury stock: at cost, 92,648 and 88,504 shares as of March 31, 2018 and December 31, 2017, respectively	380,335	322,735
Additional paid-in capital	1,770,801	1,781,059
Accumulated deficit	(319,271)	(338,150)
Accumulated other comprehensive loss	(2,181)	(1,985)
Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity	1,071,720	1,120,882
Non-controlling interest	38,400	39,190
Total stockholders’ equity	1,110,120	1,160,072
Total liabilities and stockholders’ equity	$ 4,370,212	$ 4,230,150

CONSOLIDATED BALANCE SHEETS (U3

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 44,652	$ 37,735
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	270,601,000	269,335,000
Common stock, shares outstanding	177,953,000	180,832,000
Treasury stock at cost, shares	92,648,000	88,504,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue:
Software delivery, support and maintenance	$ 329,766	$ 268,188
Client services	184,160	145,287
Total revenue	513,926	413,475
Cost of revenue:
Software delivery, support and maintenance	104,410	83,397
Client services	154,768	124,939
Amortization of software development and acquisition-related assets	33,773	26,487
Total cost of revenue	292,951	234,823
Gross profit	220,975	178,652
Selling, general and administrative expenses	143,070	110,845
Research and development	69,977	49,232
Amortization of intangible and acquisition-related assets	12,248	7,312
(Loss) income from operations	(4,320)	11,263
Interest expense	(25,046)	(20,180)
Other (loss) income, net	(917)	239
Impairment of and losses on long-term investments	(5,500)	0
Equity in net (loss) income of unconsolidated investments	(61)	285
Loss from continuing operations before income taxes	(35,844)	(8,393)
Income tax benefit (provision)	2,914	(172)
Loss from continuing operations, net of tax	(32,930)	(8,565)
Income from discontinued operations, net of tax	4,415	0
Net loss	(28,515)	(8,565)
Less: Net loss (income) attributable to non-controlling interests	790	(453)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(12,149)	(10,962)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (39,874)	$ (19,980)
Basic
Continuing operations	$ (0.25)	$ (0.11)
Discontinued operations	0.03	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	(0.22)	(0.11)
Diluted
Continuing operations	(0.25)	(0.11)
Discontinued operations	0.03	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ (0.22)	$ (0.11)

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (28,515)	$ (8,565)
Other comprehensive income (loss):
Foreign currency translation adjustments	123	1,515
Change in unrealized gain (loss) on available for sale securities	0	(74,702)
Change in fair value of derivatives qualifying as cash flow hedges	(633)	1,348
Other comprehensive loss before income tax benefit (expense)	(510)	(71,839)
Income tax benefit (expense) related to items in other comprehensive loss	314	(521)
Total other comprehensive loss	(196)	(72,360)
Comprehensive loss	(28,711)	(80,925)
Less: Comprehensive loss (income) attributable to non-controlling interests	790	(453)
Comprehensive loss, net	$ (27,921)	$ (81,378)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net (loss) income	$ (28,515)	$ (8,565)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	65,912	49,694
Stock-based compensation expense	11,952	7,946
Deferred taxes	(5,048)	(1,570)
Impairment of and losses on long-term investments	5,500	0
Equity in net loss (income) of unconsolidated investments	61	(285)
Other losses, net	50	1,240
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable and contract assets, net	34,780	(8,010)
Prepaid expenses and other assets	(4,259)	(4,464)
Accounts payable	4,122	2,869
Accrued expenses	13,259	(5,567)
Accrued compensation and benefits	(21,074)	(5,501)
Deferred revenue	(21,319)	48,687
Other liabilities	2,887	(997)
Net cash provided by operating activities	58,308	75,477
Cash flows from investing activities:
Capital expenditures	(8,602)	(14,524)
Capitalized software	(32,227)	(34,011)
Cash paid for business acquisitions, net of cash acquired	(109,020)	(3,975)
Other proceeds from investing activities	37	0
Net cash used in investing activities	(149,812)	(52,510)
Cash flows from financing activities:
Proceeds from sale or issuance of common stock	212	0
Taxes paid related to net share settlement of equity awards	(8,496)	(5,864)
Payments of capital lease obligations	(2,804)	(3,015)
Credit facility payments	(1,217)	(86,726)
Credit facility borrowings, net of issuance costs	145,843	80,000
Repurchase of common stock	(57,599)	0
Payment of acquisition financing obligations	(3,226)	0
Net cash provided by (used in) financing activities	72,713	(15,605)
Effect of exchange rate changes on cash and cash equivalents	65	419
Net (decrease) increase in cash and cash equivalents	(18,726)	7,781
Cash, cash equivalents and restricted cash, beginning of period	162,498	96,610
Cash, cash equivalents and restricted cash, end of period	$ 143,772	$ 104,391

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2018 and 2017 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2017 (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. Change in Presentation During the first quarter of 2018, we changed the presentation of certain bundled revenue streams. Such revenue was previously included as part of software delivery, support and maintenance revenue. Under the new presentation, such revenue is included as part of client services revenue. The revenue previously reported for the first quarter of 2017 has been recast to match the new presentation by reducing software delivery, support and maintenance and increasing client services by $4.3 million. Significant Accounting Policies We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASC 606”) effective on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. There have been no other changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In January 2016, the FASB issued Accounting Standards Update No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities” In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “ Leases (Topic 842) In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2018
Business Combinations [Abstract]
Business Combinations	2. Business Combinations 2018 Business Combinations Acquisition of Practice Fusion, Inc. On February 13. 2018, we completed the acquisition of Practice Fusion, Inc., a Delaware corporation (“Practice Fusion”), for aggregate consideration of $113.7 million paid in cash. Practice Fusion offers an affordable certified cloud-based electronic health record (“EHR”) for traditionally hard-to-reach small, independent physician practices. The consideration paid for Practice Fusion is shown below: (In thousands) Aggregate purchase price $ 100,000 Add: Net working capital surplus 469 Less: Adjustment for assumed indebtedness (1,684 ) Add: Closing cash 14,951 Total consideration paid for Practice Fusion $ 113,736 The allocation of the fair value of the consideration transferred as of the acquisition date of February 13, 2018 is shown in the table below. (In thousands) Cash and cash equivalents $ 14,951 Accounts receivable, net 13,397 Prepaid expenses and other current assets 809 Fixed assets 1,764 Intangible assets 67,200 Goodwill 34,739 Other assets 43 Accounts payable and accrued expenses (7,620 ) Deferred revenue (2,400 ) Long-term deferred tax liability (8,332 ) Other liabilities (815 ) Net assets acquired $ 113,736 The following table summarizes the preliminary fair values of the identifiable intangible assets and their estimated useful lives: Useful Life Fair Value Description (In years) (In thousands) Customer Relationships - Physician Practices 15 $ 28,700 Customer Relationships - Pharmaceutical Partners 20 19,800 Technology 8 14,800 Tradenames 10 3,900 $ 67,200 We incurred $0.5 million of acquisition costs which are included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the quarter ended March 31, 2018. The results of operations of Practice Fusion were not material to our consolidated results of operations for the quarter ended March 31, 2018. Other Acquisitions and Divestiture On February 6, 2018 the Company acquired all of the common stock of a cloud-based analytics software platform provider for a purchase price of $8.0 million in cash. The allocation of the consideration is as follows: $3.7 million of intangible assets related to technology; $0.6 million to customer relationships; $4.8 million of goodwill; $0.8 million to accounts receivable; accounts payable of $0.2 million; deferred revenue of $0.6 million and $1.1 million of long-term deferred income tax liabilities. This allocation is preliminary and subject to changes, which could be significant, as appraisals of tangible and intangible assets are finalized, and additional information becomes available. The acquired intangible asset related to the technology will be amortized over 8 years using a method that approximates the pattern of economic benefits to be gained by the intangible asset. The customer relationship will be amortized over one year. The goodwill is not deductible for tax purposes. The results of operations of this acquisition were not material to our consolidated results of operations for the three months ended March 31, 2018. On January 31, 2018, Netsmart (as defined below) entered into a Unit Purchase Agreement with a third party provider of billing solutions, for aggregate consideration of $5.4 million, plus net working capital consideration relative to a predetermined target, to acquire 100% of the equity of the entity. This transaction has been accounted for as a business combination. Of the total consideration, $2.0 million was paid in cash at closing with the remaining $3.6 million to be paid evenly on the first and second anniversaries of closing. This transaction resulted in the preliminary recognition of goodwill of $1.4 million The purchase accounting for this transaction has not yet been completed. On March 15, 2018, we entered into an agreement with a third party to contribute certain assets and liabilities of our strategic sourcing business unit, acquired as part of the acquisition of the EIS Business in 2017 discussed below, into a new entity. We were also obligated to contribute $2.7 million of cash as additional consideration, which was paid during April 2018. In exchange for our contributions, we obtained a 35.7% interest in the new entity, which was valued at $4.0 million and is included in Other assets in our consolidated balance sheet as of March 31, 2018. This investment will be accounted for under the equity method of accounting. As a result of this transaction, we recognized a loss of $0.9 million, which is included on the “Other (loss)/income, net” line in our consolidated statement of operations for the three months ended March 31, 2018. Pre-2018 Business Combination Updates Acquisition of DeVero On July 17, 2017, Netsmart completed the acquisition of DeVero, Inc. (“DeVero”), a healthcare technology company that develops electronic medical record solutions for home healthcare and hospice, for an aggregate purchase price of $50.5 million in cash. At March 31, 2018 the allocation of the purchase price is final and there were no measurement period adjustments recorded during the three months ended March 31, 2018. Acquisition of the Patient/Provider Engagement Solutions Business from NantHealth, Inc. On August 25, 2017, the Company completed the acquisition of substantially all of the assets relating to the provider/patient engagement solutions business of NantHealth, Inc. (“NantHealth”). During the three months ended March 31, 2018, measurement period adjustments to the purchase price allocation were recorded which resulted in an increase in goodwill of $0.1 million. At March 31, 2018 the purchase price allocation remains subject to further adjustment, primarily with respect to net working capital acquired. Acquisition of the Enterprise Information Solutions Business from McKesson Corporation On October 2, 2017, Allscripts Healthcare, LLC, a wholly-owned subsidiary of the Company (“Healthcare LLC”), completed the acquisition of McKesson Corporation’s Enterprise Information Solutions Business division (the “EIS Business”), which provides certain software solutions and services to hospitals and health systems, by acquiring all of the outstanding equity interests of two indirect, wholly-owned subsidiaries of McKesson Corporation. The acquisition of the EIS Business was based on a total enterprise value of $185 million. During the three months ended March 31, 2018, measurement period adjustments to the purchase price allocation were recorded which resulted in an increase in goodwill of $37.7 million, primarily resulting from an increase in deferred revenue of $44.0 million partially offset by increases in identified intangible assets of $6.6 million. At March 31, 2018 the purchase price allocation remains subject to further adjustment, primarily with respect to certain acquired intangible assets and deferred revenue. Formation of Joint Business Entity and Acquisition of Netsmart, Inc. On March 20, 2016, we entered into a Contribution and Investment Agreement with GI Netsmart Holdings LLC, a Delaware limited liability company (“GI Partners”), to form a joint business entity to which we contributed our Homecare TM TM As part of the Netsmart Transaction, we deposited $15 million in an escrow account to be used by Netsmart to facilitate the integration of our Homecare TM business within Netsmart over the next five years, at which time the restriction on any unused funds will lapse. As of March 31, 2018, there is $9.0 million remaining in the escrow account. Supplemental Information The supplemental pro forma results below were calculated after applying our accounting policies and adjusting the results of the EIS Business and NantHealth to reflect (i) the additional amortization that would have been charged resulting from the fair value adjustments to intangible assets (ii) the additional interest expense associated with Allscripts’ borrowings under its revolving facility, and (iii) the additional amortization of the estimated adjustment to decrease the assumed deferred revenue obligations to fair value that would have been charged assuming both acquisitions occurred on January 1, 2016, together with the consequential tax effects. The revenue and earnings of the EIS Business, since October 2, 2017, and NantHealth, since August 25, 2017, are included in our consolidated statement of operations for the three months ended March 31, 2018. The below supplemental pro forma revenue and net loss of the combined entity is presented as if both acquisitions had occurred on January 1, 2016. (In thousands, except per share amounts) Three Months Ended March 31, 2017 Supplemental pro forma data for combined entity: Revenue $ 520,810 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (17,572 ) Loss per share, basic and diluted $ (0.10 )

Fair Value Measurements and Lon

Fair Value Measurements and Long-term Investments	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements and Long-term Investments	3. Fair Value Measurements and Long-term Investments Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. We held no Level 1 financial instruments at March 31, 2018 or December 31, 2017. Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Level 3: Unobservable inputs that are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option asset and the 1.25% embedded cash conversion option liability that are not actively traded. These derivative instruments were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity of changes in the unobservable inputs to the option pricing model for these instruments is substantially mitigated. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. The sensitivity of changes in the unobservable inputs to the valuation pricing model used to value these instruments is not material to our consolidated results of operations. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet March 31, 2018 December 31, 2017 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 1.25% Call Option Other assets $ 0 $ 0 $ 25,410 $ 25,410 $ 0 $ 0 $ 46,578 $ 46,578 1.25% Embedded cash conversion option Other liabilities 0 0 (26,446 ) (26,446 ) 0 0 (47,777 ) (47,777 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 503 0 503 0 1,136 0 1,136 Total $ 0 $ 503 $ (1,036 ) $ (533 ) $ 0 $ 1,136 $ (1,199 ) $ (63 ) Long-term Investments The following table summarizes our long-term equity investments which are included in other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except # of investees) at March 31, 2018 Investment March 31, 2018 December 31, 2017 Equity method investments (1) 4 $ 5,658 $ 7,197 $ 3,258 Cost method investments 7 32,784 21,820 26,755 Total equity investments 11 $ 38,442 $ 29,017 $ 30,013 _________________________________ (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. As of March 31, 2018, it is not practicable to estimate the fair value of our non-marketable cost and equity method investments primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations, the issuer’s subsequent or planned raises of capital, and observable price changes in orderly transactions. Impairment of Long-term Investments Each quarter, management performs an assessment of each of our investments on an individual basis to determine if there have been any declines in fair value. As a result of this review, we recognized a non-cash impairment charge of $5.5 million related to one of our cost-method equity investments and a related note receivable, which had cost bases of $4.9 million and $2.6 million, respectively, prior to the impairment. Long-term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our senior secured credit facility and Netsmart’s Credit Agreements (as defined in Note 8, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as March 31, 2018, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 8, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Shareholders' Equity	4. Stockholders' Equity Stock-based Compensation Expense Stock-based compensation expense recognized during the three months ended March 31, 2018 and 2017 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. In addition, the three-month periods ended March 31, 2018 and 2017 include stock-based compensation expense related to Netsmart’s time-based liability classified option awards. No stock-based compensation costs were capitalized during the three months ended March 31, 2018 and 2017. Three Months Ended March 31, (In thousands) 2018 2017 Cost of revenue: Software delivery, support and maintenance $ 616 $ 1,125 Client services 1,436 1,572 Total cost of revenue 2,052 2,697 Selling, general and administrative expenses 7,245 3,550 Research and development 2,841 2,589 Total stock-based compensation expense $ 12,138 $ 8,836 Allscripts Long-Term Incentive Plan We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three months ended March 31, 2018 and 2017. We granted stock-based awards as follows: Three Months Ended March 31, 2018 Weighted-Average Grant Date (In thousands, except per share amounts) Shares Fair Value Service-based restricted stock units 1,300 $ 14.20 Performance-based restricted stock units with a service condition 524 $ 15.74 Market-based restricted stock units with a service condition 0 $ 0.00 1,824 $ 14.64 During the three months ended March 31, 2018, and the year ended December 31, 2017, 1.3 million and 1.3 million shares of common stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards. Net Share-settlements Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the three months ended March 31, 2018 and 2017 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the three months ended March 31, 2018 and 2017 were 609 thousand and 494 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Stock Repurchases On November 17, 2016, we announced that our Board approved a stock purchase program under which we may repurchase up to $200 million of our common stock through December 31, 2019. During the three months ended March 31, 2018, we repurchased 4.1 million shares of our common stock under the program for a total of $57.6 million. The approximate dollar value of shares that may yet be purchased under the program as of March 31, 2018 was $106.4 million. Netsmart Stock-based Compensation Expense Stock-based compensation expense (benefit) related to Netsmart’s time-based liability classified option awards totaled $1.2 million and ($3.5) million during the three months ended March 31, 2018 and 2017, respectively. At March 31, 2018, the liability for outstanding awards was $9.2 During the three months ended March 31, 2018, no option unit awards were granted by Netsmart .

Earnings (Loss) Per Share

Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	5. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method. The calculations of earnings (loss) per share are as follows: Three Months Ended March 31, (In thousands, except per share amounts) 2018 2017 Basic Loss per Common Share: (Loss) income from continuing operations, net of tax $ (32,930 ) $ (8,565 ) Less: Net loss (income) attributable to non-controlling interests 790 (453 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (12,149 ) (10,962 ) Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (44,289 ) $ (19,980 ) Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders 4,415 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (39,874 ) $ (19,980 ) Weighted-average common shares outstanding 179,882 180,767 Basic Loss from continuing operations per Common Share $ (0.25 ) $ (0.11 ) Basic Income from discontinued operations per Common Share 0.03 0.00 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ (0.22 ) $ (0.11 ) Diluted Loss per Common Share: (Loss) income from continuing operations, net of tax $ (32,930 ) $ (8,565 ) Less: Net loss (income) attributable to non-controlling interests 790 (453 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (12,149 ) (10,962 ) Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (44,289 ) $ (19,980 ) Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders 4,415 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (39,874 ) $ (19,980 ) Weighted-average common shares outstanding 179,882 180,767 Plus: Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 Weighted-average common shares outstanding assuming dilution 179,882 180,767 Diluted Loss from continuing operations per Common Share $ (0.25 ) $ (0.11 ) Diluted Income from discontinued operations per Common Share 0.03 0.00 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ (0.22 ) $ (0.11 ) As a result of the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the three months ended March 31, 2018 and 2017, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for that period, since the inclusion of any stock equivalents would be anti-dilutive. The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended March 31, (In thousands) 2018 2017 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 23,208 26,689

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: March 31, 2018 December 31, 2017 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 693,844 $ (419,081 ) $ 274,763 $ 695,354 $ (405,114 ) $ 290,240 Customer contracts and relationships 948,703 (475,407 ) 473,296 922,492 (464,860 ) 457,632 Total $ 1,642,547 $ (894,488 ) $ 748,059 $ 1,617,846 $ (869,974 ) $ 747,872 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 79,000 Goodwill 2,051,437 2,004,953 Total $ 2,130,437 $ 2,083,953 Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2018 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2017 $ 861,615 $ 431,132 $ 712,206 $ 2,004,953 Additions arising from business acquisitions: Practice Fusion acquisition 34,739 0 0 34,739 Other acquisitions 4,829 0 1,374 6,203 Total arising from business acquisitions 39,568 0 1,374 40,942 Increases (decreases) due to measurement period adjustments: NantHealth provider/patient solutions business 0 117 0 117 Enterprise Information Solutions business 9,204 28,454 0 37,658 Other measurement period adjustments (205 ) 0 0 (205 ) Total increases (decreases) due to measurement period adjustments: 8,999 28,571 0 37,570 Total additions to goodwill 48,567 28,571 1,374 78,512 Divestitures (30,105 ) (2,198 ) 0 (32,303 ) Foreign exchange translation 275 0 0 275 Balance as of March 31, 2018 $ 880,352 $ 457,505 $ 713,580 2,051,437 There were no accumulated impairment losses associated with our goodwill as of March 31, 2018 or December 31, 2017. Additions during the first quarter of 2018 include goodwill of $34.7 million arising from Allscripts’ purchase of Practice Fusion, Inc. Other additions during the first quarter of 2018 include $4.8 million arising from Allscripts’ purchase of a third party cloud-based analytics software platform provider, and $1.4 million arising from Netsmart’s acquisition of a third party provider of billing solutions. Measurement period adjustments include $37.7 million related to the 2017 purchase of the EIS Business. Goodwill was reduced by $2.2 million due to the divestiture of our strategic sourcing business unit, and by $30.1 million related to the OneContent business, which is classified as held for sale at March 31, 2018. Refer to Note 2, “Business Combinations,” for additional information regarding these transactions. Effective January 1, 2018, we made organizational changes that affected the Clinical and Financial Solutions, and Population Health reportable segments. Refer to Note 14, “Business Segments” for additional information. As a result of these changes, the dbMotion business unit, formerly included in the Population Health operating segment within the Population Health reportable segments, is now aligned with the Hospitals and Health Systems operating segment within the Clinical and Financial solutions reportable segment. We performed our annual goodwill impairment test as of October 1, 2017, our annual testing date, and again as of January 1, 2018 in connection with the organizational changes referred to above. While there was no impairment indicated as a result of the January 1, 2018 test, the estimated fair value of our Hospitals and Health Systems reporting unit exceeded the unit’s carrying value by 10%. As of March 31, 2018, the goodwill allocated to the Hospitals and Health Systems reporting unit was $511.2 million. The determination of the fair value of our reporting units is based on a combination of a market approach, that considers benchmark company market multiples, and an income approach, that utilizes discounted cash flows for each reporting unit and other Level 3 inputs. Under the income approach, we determine fair value based on the present value of the most recent cash flow projections for each reporting unit as of the date of the analysis and calculate a terminal value utilizing a terminal growth rate. The significant assumptions under this approach include, among others: income projections, which are dependent on sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate, and the terminal growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions such as our expectations of future performance and the expected future economic environment, which are partly based upon our historical experience. Our estimates are subject to change given the inherent uncertainty in predicting future results. Additionally, the discount rate and the terminal growth rate are based on our judgment of the rates that would be utilized by a hypothetical market participant. As part of the goodwill impairment testing, we also consider our market capitalization in assessing the reasonableness of the combined fair values estimated for our reporting units. Because the fair value of the Hospitals and Health Systems reporting unit was not substantially in excess of its carrying value at January 1, 2018, there is an increased risk that any adverse trends in the foregoing assumptions with respect to the Hospitals and Health Systems reporting unit could cause the estimated fair value to fall below the carrying value, which would result in an impairment of the reporting unit’s goodwill.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2018
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	7. Revenue from Contracts with Customers Our two primary revenue streams are (i) software delivery, support and maintenance and (ii) client services. Software delivery revenue consists of all of our proprietary software sales (either as a perpetual or term license delivery model), transaction-related revenue and the resale of hardware and third-party software. Support and maintenance revenue consists of revenue from post contract client support and maintenance services, which includes telephone support services, maintaining and upgrading software and ongoing enhanced maintenance. Client services revenue consists of revenue from managed services solutions, such as private cloud hosting, outsourcing and revenue cycle management, as well as other client services or project-based revenue from implementation, training and consulting services. In addition, for some clients, we host the software applications licensed from us using our own or third-party servers. For other clients, we offer an outsourced service in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees. Adoption of New Revenue Standard In May 2014, the FASB issued ASC 606 to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASC 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASC 606 defines a five-step process to achieve this principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under the previous ASC 605, Revenue Recognition The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). We have adopted the standard effective on January 1, 2018 using the modified retrospective method. We also implemented internal controls and updated our processes and key systems to allow us to comply with the new requirements. The reported results for the three months ended March 31, 2018 reflect the adoption of ASC 606. The comparative information for the three months ended March 31, 2017 has not been restated and will continue to be reported under the previous guidance of ASC 605, which was in effect during that period. The following adjustments were made to balances previously reported on the condensed consolidated balance sheet as of December 31, 2017: As Reported Adjustments Adjusted (In thousands, except per share amounts) December 31, 2017 due to ASC 606 January 1, 2018 Accounts receivable, net $ 567,873 $ (32,529 ) $ 535,344 Contract assets 0 76,509 76,509 Prepaid expenses and other current assets 115,463 11,646 127,109 Deferred revenue, current 546,830 (7,453 ) 539,377 Deferred revenue, long-term 24,047 0 24,047 Deferred taxes, net 93,643 16,478 110,121 Accumulated deficit (338,150 ) 46,601 (291,549 ) The adoption of ASC 606 had no impact on cash from or used in operating, financing or investing activities reported in our consolidated statement of cash flows for the year ended December 31, 2017. The following tables compare the reported consolidated balance sheet and statement of operations as of and for the three months ended March 31, 2018, to the pro-forma amounts assuming the previous guidance of ASC 605 had been in effect: March 31, 2018 (In thousands, except per share amounts) As reported under ASC 606 Adjustments due to ASC 606 Pro forma under ASC 605 Accounts receivable, net $ 495,695 $ 78,302 $ 573,997 Contract assets 45,068 (45,068 ) 0 Prepaid expenses and other current assets 130,051 33 130,084 Contract assets - long-term 40,486 (40,486 ) 0 Deferred revenue, current 540,289 (972 ) 539,317 Deferred taxes, net 117,061 (1,629 ) 115,432 Accumulated deficit (319,271 ) (4,618 ) (323,889 ) Three Months Ended March 31, 2018 (In thousands, except per share amounts) As reported under ASC 606 Adjustments due to ASC 606 Pro forma under ASC 605 Software delivery, support and maintenance $ 329,766 $ (5,028 ) $ 324,738 Client services 184,160 (1,066 ) 183,094 Gross profit 220,975 (6,279 ) 214,696 Selling, general and administrative expenses 143,070 (218 ) 142,852 Loss from operations (4,320 ) (6,061 ) (10,381 ) Loss from continuing operations before income taxes (35,844 ) (6,247 ) (42,091 ) Income tax benefit 2,914 1,629 4,543 Net loss (28,515 ) (4,618 ) (33,133 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (39,874 ) (4,618 ) $ (44,492 ) Loss per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (0.22 ) (0.03 ) $ (0.25 ) Loss per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (0.22 ) (0.03 ) $ (0.25 ) The recognition of revenue related to hardware sales, software-as-a-service-based offerings, client services, electronic data interchange services, and managed services remained substantially unchanged under ASC 606. The adoption of ASC 606 resulted in an increase in contract assets driven by upfront recognition of revenue, rather than over the subscription period, from certain multi-year software subscription contracts that include both software licenses and software support and maintenance. Costs to Obtain or Fulfill a Contract Under ASC 605, we only capitalized direct sales commissions that were specifically associated with new or renewal contracts. The new revenue recognition guidance under ASC 606 requires the capitalization of all incremental costs of obtaining a contract with a customer that an entity expects to recover. As part of our implementation efforts, we identified certain indirect commissions and other payments that would be eligible for capitalization under ASC 606 as they are incremental costs solely associated with new or renewal contracts that we expect to recover. Certain costs related to the fulfillment of contracts will also be capitalized. As a result, we recorded a deferral for such costs of $8.6 million, net of tax, upon adoption of the new guidance on January 1, 2018, which was included in the cumulative effect of initially applying ASC 606. Capitalized costs to obtain or fulfill a contract are amortized over periods ranging from two to nine years which represent the contract term or a longer period, if renewals are expected and the renewal commission, if any, is not commensurate with the initial commission. We classify such capitalized costs as current or non-current based on the expected timing of expense recognition. The current and non-current portion are included in prepaid expenses and other current assets, and other assets, respectively, in our consolidated balance sheets. At March 31, 2018, we had $27.4 million of capitalized costs to obtain or fulfill a contract. During the three months ended March 31, 2018, we recognized $8.2 million of amortization expense related to such capitalized costs, of which $8.1 million is included in selling, general and administrative expenses and $0.1 million is included in cost of revenue, in our consolidated statements of operations. Contract Balances The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivables, contract assets and customer advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as current or long-term based on the timing of when we expect to recognize revenue. In general, with the exception of fixed fee project-based client service offerings (such as implementation services), we sell our software solutions on date-based milestone events where control transfers and use of the software occurs on the delivery date but the associated payments for the software license occur on future milestone dates. In such instances, unbilled amounts are included in contract assets since our right to receive payment is conditional upon the continued functionality of the software and the provision of ongoing support and maintenance. Our fixed fee project-based client service offerings typically require us to provide the services with either a significant portion or all amounts due prior to service completion. Since our right to payment is not unconditional, amounts associated with work prior to the completion date are also deemed to be contract assets. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account in ASC 606. A performance obligation is considered distinct when both (i) a customer can benefit from the product or service either on its own or together with other resources that are readily available to the customer and (ii) the promised product or service is separately identifiable from other promises in the contract. Activities related to the fulfillment of a contract that do not transfer products or services to a customer, such as contract preparation or legal review of contract terms, are not deemed to be performance obligations. Based on the similarities in the definitions of a “deliverable” under ASC 605 and “performance obligation” under ASC 606, our identification of performance obligations did not result in a significant divergence from our existing identification approach. We generally sell our solutions through multi-element arrangements where we provide the customer with (1) software license, (2) support and maintenance, (3) embedded content such as third-party software and (4) client services. Incremental solutions, such as hardware and managed services are also provided based upon a customer’s preferences and requirements. We deem that a customer is typically able to benefit from a product or service on its own or together with readily available resources when we sell such product or service on a standalone basis. We have historically sold the majority of our performance obligations with the exception of software licenses, on a standalone basis. Incremental solutions, such as hardware, client services and managed services, are often negotiated and fulfilled on an independent sales order basis as customer needs and requirements grow over the course of a relationship period. In addition, support and maintenance and embedded content are provided on a stand-alone basis through the renewal process. One of the product offerings under our CareInMotion TM Additionally, our support and maintenance obligations include multiple discrete performance obligations, with the two largest being unspecified product upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the multiple discrete performance obligations within our overall support and maintenance obligations can be viewed as a single performance obligation since both the unspecified upgrades and technical support are activities to fulfill the maintenance performance obligation and are rendered concurrently. Generally, we do not provide additional warranties to clients above and beyond warranties that the solutions purchased will perform in accordance with the agreed-upon specifications. On rare occasions, when additional warranties are granted, we evaluate on a case-by-case basis whether the additional warranty represents a separate performance obligation. The breakdown of revenue recognized related to various performance obligations and elected accounting expedients is presented in the table below: (In thousands) Three Months Ended March 31, 2018 Revenue related to deferred revenue balance at beginning of period $ 204,297 Revenue related to new performance obligations satisfied during the period 257,222 Revenue recognized under "right-to-invoice" expedient 49,638 Reimbursed travel expenses, shipping and other revenue 2,769 Total revenue $ 513,926 The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations (commonly referred to as “backlog”) represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Total backlog equaled $4.7 billion as of March 31, 2018, of which we expect to recognize approximately 36% over the next 12 months, and the remaining 64% thereafter. Accounting Policy Elections and Practical Expedients The majority of our contracts contain provisions that require customer payment no later than one year from the transfer of control of the related performance obligation. Perpetual software license contracts in which payments range from 2 to 10 years contain a financing component. Interest income is recognized in these circumstances and totaled $0.2 million during the three months ended March 31, 2018. We have elected to exclude from the measurement of the transaction price all taxes (e.g. sales, use, value-added, etc.) assessed by government authorities and collected from a customer. Therefore, revenue is recognized net of such taxes. Within the normal course of business, we contract with customers to deliver and ship tangible products such as computer hardware or licensed software disks. In these situations, the control of the products transfers to the customer when the product reaches the shipper based on free on board (FOB) shipping clauses. We have elected to use the practical expedient allowed under ASC 606 to account for shipping and handling activities that occur after the customer has obtained control of a promised good as fulfillment costs rather than as an additional promised service and, therefore, we do not allocate a portion of the transaction price to a shipping service obligation. Instead, we record as revenue any amounts billed to customers for shipping and handling costs and record as cost of revenue the actual shipping costs incurred. Additionally, our standard contract terms allow for the reimbursement by the customer for certain travel expenses necessary to provide on-site services to customer, such as implementation and training. Such reimbursed travel expenses are reported on a gross basis. Since such reimbursed travel expenses do not represent a distinct good or service nor represent incremental value provided to the customer, a performance obligation is deemed not to exist. In certain situations, however, when the allowable reimbursable expenses amount is capped, we believe that such cap represents the most likely amount of variable consideration and the capped amount is included in the total contract transaction price. In accordance with ASC 606, if an entity has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of the entity’s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice (“right-to-invoice” practical expedient). We have elected to utilize this expedient as it relates to transaction-based services (such as revenue cycle management) and electronic data interchange transactions. Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware where we determined that a customer obtains control of the asset upon delivery, shipment or granting of access. The following table summarizes the pattern of revenue recognition for our most significant performance obligations: Performance Obligation Revenue Recognition Pattern Measure of progress Support and maintenance (SMA) Over time Output method (time elapsed) – revenue is recognized ratably over the contract term Software as a service (SaaS) Over time Output method (time elapsed) – revenue is recognized ratably over the contract term Private Cloud Hosting Over time Output method (time elapsed) – revenue is recognized ratably over the contract term Client/Education Services Over time Input method (cost to cost) – revenue is recognized proportionally over the service implementation based on hours Outsourcing services Over time Input method (cost to cost) – revenue is recognized proportionally over the outsourcing period Payerpath (transaction volume) Over time Output method ("right-to-invoice" practical expedient) – value transferred to the customer is reflected on invoicing. Software Licenses Point in time Upon shipment or electronically delivered, as applicable Hardware Point in time Upon shipment When evaluating our SMA, SaaS and private cloud hosting performance obligations, we noted that these obligations are fulfilled as stand-ready obligations to perform and, therefore, we deem the obligations to be satisfied evenly over time. Client services, such as those relating to implementation, consulting, training or education, are generally not fulfilled evenly over the contract period but rather over a shorter timeline where work effort can rise, or decline based upon stages of the project work effort. These client services are typically quoted to a customer as a fixed fee amount that covers the implementation effort. Delivery progress for these services is measured by establishing an approved cost budget with labor hour inputs utilized to gauge percentage of completion of the work effort. Therefore, revenue for our client, education and outsourcing services is recognized proportionally with the progress of the implementation work effort. Payerpath transaction volume and other transaction-based service obligations, such as revenue cycle management services, are fulfilled over time but are not provided evenly over the contract period and reliable inputs are not available to track progress of completion. We determined that value is provided to the customer throughout the contract period and the pricing charged to the customer varies on a monthly basis, based upon the volume of the customer’s transactions processed in that respective period. The invoiced amount to the customer represents this value and accordingly the practical expedient to recognize revenue based upon invoicing is most appropriate. We considered the specific implementation guidance for accounting for licenses of intellectual property (“IP”) to determine if point in time or over time recognition was more appropriate. The first step in the licensing framework is to determine whether the license is distinct or combined with other goods and services. For most of our software licensing products, the licenses are distinct, with the exception of one of our product offerings under our CareInMotion TM Disaggregation of Revenue We disaggregate our revenue from contracts with customers based on the type of revenue and nature of revenue stream, as we believe those categories best depict how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments: Three Months Ended March 31, (In thousands) 2018 2017 Revenue: Software delivery, support and maintenance Recurring revenue $ 294,455 $ 227,450 Non-recurring revenue 35,311 40,738 Total software delivery, support and maintenance 329,766 268,188 Client services Recurring revenue $ 122,474 $ 101,779 Non-recurring revenue 61,686 43,508 Total client services 184,160 145,287 Total revenue $ 513,926 $ 413,475 Three Months Ended March 31, 2018 (In thousands) Clinical and Financial Solutions Population Health Netsmart Unallocated Discontinued Operations Total Software delivery, support and maintenance $ 230,557 $ 61,198 $ 49,245 $ 1,165 $ (12,399 ) $ 329,766 Client services 143,422 8,507 33,241 (3,113 ) 2,103 184,160 Total revenue $ 373,979 $ 69,705 $ 82,486 $ (1,948 ) $ (10,296 ) $ 513,926 Three Months Ended March 31, 2017 (In thousands) Clinical and Financial Solutions Population Health Netsmart Unallocated Discontinued Operations Total Software delivery, support and maintenance $ 178,330 $ 39,689 $ 46,496 $ 3,673 $ 0 $ 268,188 Client services 117,850 3,741 26,511 (2,815 ) 0 145,287 Total revenue $ 296,180 $ 43,430 $ 73,007 $ 858 $ 0 $ 413,475

Debt

Debt	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Debt	8. Debt Debt outstanding, excluding capital leases, consists of the following: March 31, 2018 December 31, 2017 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 32,571 $ 312,429 $ 345,000 $ 35,978 $ 309,022 Senior Secured Credit Facility 778,750 7,371 771,379 628,750 3,360 625,390 Netsmart Non-Recourse Debt: First Lien Term Loan 478,099 10,420 467,679 479,316 10,950 468,366 Second Lien Term Loan 167,000 7,047 159,953 167,000 7,418 159,582 Total debt $ 1,768,849 $ 57,409 $ 1,711,440 $ 1,620,066 $ 57,706 $ 1,562,360 Less: Debt payable within one year - excluding Netsmart 20,000 497 19,503 28,125 438 27,687 Less: Debt payable within one year - Netsmart 4,866 2,106 2,760 4,866 2,111 2,755 Total long-term debt, less current maturities $ 1,743,983 $ 54,806 $ 1,689,177 $ 1,587,075 $ 55,157 $ 1,531,918 Interest expense consists of the following: Three Months Ended March 31, (In thousands) 2018 2017 Interest expense $ 7,938 $ 4,834 Amortization of discounts and debt issuance costs 3,756 3,581 Netsmart: Interest expense (1) 12,451 10,917 Amortization of discounts and debt issuance costs 901 848 Total interest expense $ 25,046 $ 20,180 (1) Includes interest expense related to capital leases. Interest expense related to the 1.25% Notes, included in the table above, consists of the following: Three Months Ended March 31, (In thousands) 2018 2017 Coupon interest at 1.25% $ 1,078 $ 1,078 Amortization of discounts and debt issuance costs 3,407 3,246 Total interest expense related to the 1.25% Notes $ 4,485 $ 4,324 Allscripts Senior Secured Credit Facility On February 15, 2018, Allscripts and Healthcare LLC entered into a Second Amended and Restated Credit Agreement (the “Second Amended Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”), the several banks and other financial institutions or entities from time to time party thereto, and Fifth Third Bank, KeyBank National Association, SunTrust Bank and Wells Fargo Bank, National Association, as syndication agents, amending and restating the Amended and Restated Credit Agreement, dated September 30, 2015, as amended on March 28, 2016 and December 22, 2016 (the “Existing Credit Agreement”). The Second Amended Credit Agreement provides for a $400 million senior secured term loan (an increase from the $250 million term loan provided under the Existing Credit Agreement) (the “Term Loan”) and a $900 million senior secured revolving facility (an increase from the $550 million revolving facility provided under the Existing Credit Agreement) (the “Revolving Facility”), each with a five-year term. The Term Loan is repayable in quarterly installments commencing on June 30, 2018. A total of up to $50 million of the Revolving Facility is available for the issuance of letters of credit, up to $10 million of the Revolving Facility is available for swingline loans, and up to $100 million of the Revolving Facility could be borrowed under certain foreign currencies. Proceeds from the borrowings under the Second Amended Credit Agreement were used for the refinancing of loans under the Existing Credit Agreement. The proceeds of the Revolving Facility can be used to finance Allscripts’ working capital needs and for general corporate purposes, including, without limitation, financing of permitted acquisitions, and for share repurchases. Allscripts is also permitted to add one or more incremental revolving and/or term loan facilities in an aggregate amount of up to $600 million, subject to certain conditions (an increase from the $300 million incremental facility permitted under the Existing Credit Agreement). The initial applicable interest rate margin for Base Rate borrowings is 1.00%, and for Eurocurrency Rate borrowings is 2.00%. On and after September 30, 2018, the interest rate margins will be determined from a pricing table and will depend upon Allscripts’ total leverage ratio. The applicable margins for Base Rate borrowings under the Second Amended Credit Agreement range from 0.50% to 1.25% depending on Allscripts’ total leverage ratio (as compared to the 0.00% to 1.25% range provided under the Existing Credit Agreement). The applicable margins for Eurocurrency Rate loans range from 1.50% to 2.25%, depending on Allscripts’ total leverage ratio (as compared to the 1.00% to 2.25% range provided under the Existing Credit Agreement). As of March 31, 2018, $400.0 million under the Term Loan, $378.8 million under the Revolving Facility, and $0.8 million in letters of credit were outstanding under the Second Amended Credit Agreement. As of March 31, 2018, the interest rate on the borrowings under the Second Amended Credit Agreement was LIBOR plus 2.00%, which totaled 3.88%. We were in compliance with all covenants under the Second Amended Credit Agreement as of March 31, 2018. As of March 31, 2018, we had $520.4 million available, net of outstanding letters of credit, under our Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of our Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. As of March 31, 2018, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount. Netsmart Non-Recourse Debt As of March 31, 2018, $478.1 million under the Netsmart First Lien Term Loan, $167.0 million under the Netsmart Second Lien Term Loan and no amounts under the Netsmart Revolving Facility (collectively, the “Netsmart Credit Agreements”) were outstanding. As of March 31, 2018, the interest rate on the borrowings under the Netsmart First Lien Term Loan was Adjusted LIBO plus 4.50%, which totaled 6.38%, the interest rate on the borrowings under the Netsmart Second Lien Term Loan was Adjusted LIBO plus 9.50%, which totaled 11.38%, and the interest rate on the borrowings under the Netsmart Revolving Facility was Adjusted LIBO plus 4.75%, which totaled 6.63%. Netsmart was in compliance with all covenants under its Netsmart Credit Agreements as of March 31, 2018. As of March 31, 2018, Netsmart had $50.0 million available, with no outstanding letters of credit commitments, under the Netsmart Revolving Facility. There can be no assurance that Netsmart will be able to draw on the full available balance of the Netsmart Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. The following table summarizes future debt payment obligations as of March 31, 2018: (In thousands) Total Remainder of 2018 2019 2020 2021 2022 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 345,000 $ 0 $ 0 $ 0 Term Loan 400,000 15,000 20,000 27,500 30,000 37,500 270,000 Revolving Facility (2) 378,750 0 0 0 0 0 378,750 Netsmart Non-Recourse Debt (2) First Lien Term Loan (3) 478,099 3,650 4,866 4,866 4,866 4,866 454,985 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Total debt $ 1,768,849 $ 18,650 $ 24,866 $ 377,366 $ 34,866 $ 42,366 $ 1,270,735 (1) (2) (3)

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes We account for income taxes under FASB Accounting Standards Codification 740, Income Taxes Three Months Ended March 31, (In thousands) 2018 2017 Loss from continuing operations before income taxes $ (35,844 ) $ (8,393 ) Income tax benefit (provision) $ 2,914 $ (172 ) Effective tax rate 8.1 % (2.0 %) The United States Tax Cuts and Jobs Act (the “Tax Act”) was enacted on December 22, 2017 and introduced significant changes to the income tax law in the United States. Effective in 2018, the Tax Act reduces the United States statutory tax rate from 35% to 21% and creates new taxes on certain foreign-sourced earnings and certain related-party payments, which are referred to as the global intangible low-taxed income tax and the base erosion tax, respectively. In addition, in 2017 we were subject to a one-time transition tax on accumulated foreign subsidiary earnings not previously subject to income tax in the United States. Due to the timing of the enactment and the complexity involved in applying the provisions of the Tax Act, we made reasonable estimates of the effects and recorded provisional benefit of $20.8 million in our financial statements for the year ended December 31, 2017 in accordance with guidance in Staff Accounting Bulletin No. 118 (SAB 118) which allows a measurement period of up to one year after the enactment date to finalize the recording of the related tax impacts. This provisional benefit includes $26 million benefit for remeasurement of deferred tax balances to reflect the lower federal rate and expense of $5.2 million for the one-time transition tax on accumulated foreign subsidiary earnings not previously subject to income tax in the United States. We will complete our analysis of the Tax Act during 2018, and any needed adjustments to the provisional amounts will be included in income tax expense or benefit in the appropriate period, in accordance with SAB 118. We are continuing to assess the impacts of the Tax Act on the 2018 effective tax rate and income tax accounting, particularly the new Global Intangible Low-taxed Income ("GILTI") tax and Base Erosion and Anti-Abuse Tax (BEAT) rules. Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance, permanent differences, income attributable to foreign jurisdictions taxed at lower rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three months ended March 31, 2018, compared with the prior year comparable period, differs primarily due to the estimated impact of the GILTI and BEAT provisions and the stricter executive compensation deduction provisions of the Tax Act, reflected in the provision for the three months ended March 31, 2018. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). Due to the level of forecasted operating income for the year ending December 31, 2018, applied to a pre-tax loss for the three months ended March 31, 2018, w Effective January 1, 2017, we adopted ASU 2016-09. The guidance in ASU 2016-09, among other things, will require all income tax effects of share-based awards to be recognized in the statement of operations when the awards vest or are settled as a discrete item in the period in which they occur. In the three months ended March 31, 2018 and 2017, we recorded $0.9 million and $1.4 million, respectively, of tax expense for awards in which the compensation cost recorded was higher than the tax deductions for the awards. In the quarter ended March 31, 2017, we recorded an offsetting release of valuation allowance in the quarter of $1.4 million. ASU 2016-09 requires entities to recognize excess tax benefits, regardless of whether the tax deduction reduces taxes payable. In the quarter ended March 31, 2017, as part of adopting the new standard, we recorded a gross cumulative effect adjustment of $5.6 million to the opening balance of accumulated deficit to create a deferred tax asset to recognize excess tax benefits not previously recorded. The net decrease to accumulated deficit was $1.8 million due to the recognition of a corresponding valuation allowance of $3.8 million. Our unrecognized income tax benefits were $12.8 million and $12.0 million as of March 31, 2018 and December 31, 2017, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted in light of changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations, and changes in tax law.

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2018
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	10. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: March 31, 2018 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 503 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 25,410 N/A 1.25% Embedded cash conversion option N/A Other liabilities 26,446 Total derivatives $ 25,913 $ 26,446 December 31, 2017 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,136 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 46,578 N/A 1.25% Embedded cash conversion option N/A Other liabilities 47,777 Total derivatives $ 47,714 $ 47,777 N/A – We define “N/A” as disclosure not being applicable Foreign Exchange Contracts We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a decreasing percentage of forecasted monthly INR expenses over time. As of March 31, 2018, there were 3 forward contracts outstanding that were staggered to mature monthly starting in April 2018 and ending in June 2018. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond June 2018. As of March 31, 2018, the notional amount of each outstanding forward contract was 120 million INR, or the equivalent of $1.8 million, based on the exchange rate between the United States dollar and the INR in effect as of March 31, 2018. These amounts also approximate the forecasted future INR expenses we target to hedge in any one month in the future. The critical terms of the forward contracts and the related hedged forecasted future expenses matched and allowed us to designate the forward contracts as highly effective cash flow hedges. The effective portion of the change in fair value is initially recorded in accumulated other comprehensive loss (“AOCI”) and subsequently reclassified to income in the period in which the cash flows from the associated hedged transactions affect income. Any ineffective portion of the change in fair value of the cash flow hedges is recognized in current period income. During the three months ended March 31, 2018, no amount was excluded from the effectiveness assessment and no gains or losses were reclassified from AOCI into income as a result of forecasted transactions that failed to occur. As of March 31, 2018, we estimate that $0.5 million of net unrealized derivative gains included in AOCI will be reclassified into income within the next twelve months. The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended March 31, 2018 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended March 31, 2018 Foreign exchange contracts $ (78 ) Cost of Revenue $ 189 Selling, general and administrative expenses 144 Research and development $ 222 Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended March 31, 2017 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended March 31, 2017 Foreign exchange contracts $ 1,873 Cost of Revenue $ 178 Selling, general and administrative expenses 137 Research and development $ 210 1.25% Call Option In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment (due to the cash settlement features) until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 3, “Fair Value Measurements and Long-term Investments.” The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in Other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal. 1.25% Notes Embedded Cash Conversion Option The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in Other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 3, “Fair Value Measurements and Long-term Investments.” The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended March 31, (In thousands) 2018 2017 1.25% Call Option $ (21,168 ) $ 17,605 1.25% Embedded cash conversion option 21,331 (17,903 ) Net (loss) gain included in other income, net $ 163 $ (298 )

Other Comprehensive Income

Other Comprehensive Income	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Other Comprehensive Income	11. Other Comprehensive Income Accumulated Other Comprehensive Loss Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2017 (1) $ (2,676 ) $ 691 $ (1,985 ) Other comprehensive income (loss) before reclassifications 123 (58 ) 65 Net losses (gains) reclassified from accumulated other comprehensive loss 0 (261 ) (261 ) Net other comprehensive income 123 (319 ) (196 ) Balance as of March 31, 2018 (2) $ (2,553 ) $ 372 $ (2,181 ) ______________________________________________________ (1) Net of taxes of $445 thousand for unrealized net gains on foreign exchange contract derivatives. (2) Net of taxes of $131 thousand for unrealized net gains on foreign exchange contract derivatives. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Available for Sale Securities (1) Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2016 (2) $ (6,028 ) $ (56,420 ) $ 619 $ (61,829 ) Other comprehensive (loss) income before reclassifications 1,515 (74,701 ) 1,146 (72,040 ) Net losses reclassified from accumulated other comprehensive loss 0 0 (320 ) (320 ) Net other comprehensive (loss) income 1,515 (74,701 ) 826 (72,360 ) Balance as of March 31, 2017 (3) $ (4,513 ) $ (131,121 ) $ 1,445 $ (134,189 ) ____________________________________________________________________________ (1) Majority of unrealized loss relates to decline in fair value of NantHealth common stock. (2) Net of taxes of $402 thousand for unrealized net gains on foreign exchange contract derivatives and $61 thousand for unrealized net gains on available for sale securities. ( 3 ) Income Tax Effects Related to Components of Other Comprehensive Income (Loss) The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended March 31, 2018 2017 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 123 $ 0 $ 123 $ 1,515 $ 0 $ 1,515 Available for sale securities: Net loss arising during the period 0 0 0 (74,702 ) 1 (74,701 ) Net loss reclassified into income 0 0 0 0 0 0 Net change in unrealized gains (losses) on available for sale securities 0 0 0 (74,702 ) 1 (74,701 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period (78 ) 20 (58 ) 1,873 (727 ) 1,146 Net (gains) losses reclassified into income (1) (555 ) 294 (261 ) (525 ) 205 (320 ) Net change in unrealized (losses) gains on foreign exchange contracts (633 ) 314 (319 ) 1,348 (522 ) 826 Net (loss) gain on cash flow hedges (633 ) 314 (319 ) 1,348 (522 ) 826 Other comprehensive income (loss) $ (510 ) $ 314 $ (196 ) $ (71,839 ) $ (521 ) $ (72,360 ) ____________________________________________ (1) Tax effects for the three months ended March 31, 2018 include $149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income at December 31, 2017.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Contingencies	12. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results. On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in the U.S. District Court for the Northern District of Illinois against us. The complaint alleges that, on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff sought $500 for each alleged violation of the TCPA, treble damages if the Court finds the violations to be willful, knowing or intentional, and injunctive and other relief. Allscripts answered the complaint denying all material allegations and asserting a number of affirmative defenses, as well as counterclaims for breach of a license agreement. On March 31, 2016, plaintiff filed its motion for class certification. On May 31, 2016, we filed our opposition to plaintiff’s motion for class certification, and simultaneously moved for summary judgment on all of plaintiff’s claims. On June 2, 2017, an order was entered denying class certification and, accordingly, the case will not proceed on a class-wide basis. The EIS Business acquired from McKesson on October 2, 2017 is subject to a May 2017 civil investigative demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of New York. The CID requests documents and information related to the certification McKesson obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program. McKesson has agreed, with respect to the CID, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition. Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney’s Office for the District of Vermont pursuant to a CID. The CID relates to the certification of Practice Fusion’s software under the U.S. Office of the National Coordinator for Health Information Technology’s electronic health record certification program, and related business practices. It has been Practice Fusion’s practice to respond to such matters in a cooperative, thorough and timely manner. To date, the CID has not led to a claim or legal proceeding against Practice Fusion. On January 25, 2018, a complaint was filed in Surfside Non-Surgical Orthopedics, P.A. v. Allscripts Healthcare Solutions, Inc. Plaintiff seeks to represent a class of customers seeking damages from Allscripts. The parties are currently engaged in limited jurisdictional discovery. Allscripts expects to respond to the complaint after this discovery is completed.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2018
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	13. Discontinued Operations Two of the product offerings acquired with the EIS Business, Horizon Clinicals and Series2000 Revenue Cycle, are to be sunset after the first quarter of 2018. The decision to discontinue these solutions was made prior to our acquisition of the EIS Business and, therefore, are presented below as discontinued operations. Until the end of the first quarter of 2018, we will be involved in ongoing maintenance and support for these solutions until customers have transitioned to other platforms. No disposal gains or losses were recognized during the three months ended March 31, 2018 related to this discontinued operation. The following table summarizes the major classes of assets and liabilities of the discontinued operation, as reported on the consolidated balance sheet as of March 31, 2018: (In thousands) March 31, 2018 December 31, 2017 Carrying amounts of major classes of assets included as part of discontinued operations: Accounts receivable, net $ 2,265 $ 8,196 Prepaid expenses and other current assets 2,680 3,080 Total assets attributable to discontinued operations $ 4,945 $ 11,276 Carrying amounts of major classes of liabilities included as part of discontinued operations: Accounts payable $ 104 $ 114 Accrued expenses 6,150 5,599 Accrued compensation and benefits 8,022 7,728 Deferred revenue 0 7,241 Other classes of liabilities that are not major 0 676 Total liabilities attributable to discontinued operations $ 14,276 $ 21,358 The following table summarizes the major classes of line items constituting income (loss) of the discontinued operation, as reported in the consolidated statements of operations for the three months ended March 31, 2018: Three months ended (In thousands) March 31, 2018 Major classes of line items constituting pretax profit (loss) of discontinued operations Revenue: Software delivery, support and maintenance $ 9,804 Client services 492 Total revenue 10,296 Cost of revenue: Software delivery, support and maintenance 2,463 Client services 743 Total cost of revenue 3,206 Gross profit 7,090 Selling, general and administrative expenses 0 Research and development 1,124 Income from discontinued operations before income taxes 5,966 Income tax provision (1,551 ) Income from discontinued operations, net of tax $ 4,415 During the three months ended March 31, 2018, the discontinued operation generated $4.3 million of cash.

Business Segments

Business Segments	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Business Segments	14. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management. During the first quarter of 2018, in an effort to further streamline and align our operating structure around our key acute and population health management solutions, we made several changes to our organizational and reporting structure. These changes included the split of our former Population Health operating segment into several components. The dbMotion business unit, formerly included in the Population Health operating segment, is now aligned with the Hospitals and Health Systems operating segment within the Clinical and Financial solutions reportable segment. The Care Management, Referral Management and Careport business units, formally included in the Population Health operating segment, were combined into a new CarePort operating segment within the Population Health reportable segment. The prior period segment disclosures below were revised to conform to the current year presentation. As of March 31, 2018, we had ten operating segments, which are aggregated into three reportable segments. The Clinical and Financial Solutions reportable segment includes the Hospitals and Health Systems, Ambulatory, Payer and Life Sciences, and EIS-Classics strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from the sale of integrated clinical software applications and financial and information solutions, which primarily include EHR-related software, connectivity and coordinated care solutions, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training and electronic claims administration services. The Population Health reportable segment is comprised of five separate operating segments: CarePort, FollowMyHealth ® TM The results of operations related to two of the product offerings acquired with the EIS Business are presented throughout these financial statements as discontinued operations and are included in the Clinical and Financial Solutions reportable segment, except for acquisition-related deferred revenue adjustments, which are included in “Unallocated Amounts”. Refer to Note 13, “Discontinued Operations”. Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and income from operations as measures of performance and to make decisions on allocation of resources. With the exception of the Netsmart segment, in determining these performance measures, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in a business acquisition. With the exception of the Netsmart segment, we also exclude the amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), which are centrally managed, as well as revenue and the associated cost from the resale of certain ancillary products, primarily hardware, other than the respective amounts associated with the Netsmart segment. The Netsmart segment, as presented, includes all revenue and expenses incurred by Netsmart since it operates as a stand-alone business entity and its resources allocation and performance are reviewed and measured at such all-inclusive level. The eliminations of intercompany transactions between Allscripts and Netsmart are included in the “Unallocated Amounts” category. We do not track our assets by segment. Three Months Ended March 31, (In thousands) 2018 2017 Revenue: Clinical and Financial Solutions $ 373,979 $ 296,180 Population Health 69,705 43,429 Netsmart 82,486 73,007 Unallocated Amounts (1,948 ) 859 Discontinued Operations (10,296 ) 0 Total revenue $ 513,926 $ 413,475 Gross Profit: Clinical and Financial Solutions $ 154,286 $ 119,261 Population Health 53,371 35,845 Netsmart 36,301 34,574 Unallocated Amounts (15,893 ) (11,028 ) Discontinued Operations (7,090 ) 0 Total gross profit $ 220,975 $ 178,652 Income (loss) from operations: Clinical and Financial Solutions $ 70,742 $ 53,582 Population Health 36,434 28,468 Netsmart 2,313 8,929 Unallocated Amounts (107,843 ) (79,716 ) Discontinued Operations (5,966 ) 0 Total income from operations $ (4,320 ) $ 11,263

Supplemental Disclosures

Supplemental Disclosures	3 Months Ended
	Mar. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	15. Supplemental Disclosures Restricted Cash The majority of the restricted cash balance as of March 31, 2018 represents Netsmart’s cash deposits to maintain two letters of credit with a financial institution related to customer agreements and an escrow fund related to a previous acquisition associated with the acquired EIS Business. Three Months Ended March 31, (In thousands) 2018 2017 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 135,003 $ 104,391 Restricted cash 8,769 - Total cash, cash equivalents and restricted cash $ 143,772 $ 104,391 Supplemental non-cash information: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart $ 12,149 $ 10,962 Obligations incurred to purchase capitalized software or enter into capital leases $ 9,786 $ 1,407 Contribution of assets in exchange for equity interest $ 4,000 $ 0

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events Completion of OneContent business divestiture On April 2, 2018, Allscripts, Healthcare LLC and certain subsidiaries of Healthcare LLC and Hyland Software, Inc., an Ohio corporation (“Hyland”), completed the transactions contemplated by an Asset Purchase Agreement (the “Asset Purchase Agreement”) by which Hyland acquired substantially all of the assets of the Allscripts’ business providing hospitals and health systems document and other content management software and services generally known as “OneContent”. Allscripts acquired the OneContent business during the fourth quarter of 2017 through the acquisition the EIS Business. Certain assets of Allscripts relating to the OneContent business were excluded from the transaction and retained by Allscripts, as described in the Asset Purchase Agreement. In addition, Hyland assumed certain liabilities related to the OneContent business under the terms of the Asset Purchase Agreement. The total consideration for the OneContent business is $260 million, which is subject to certain adjustments for liabilities assumed by the Hyland and net working capital as described in the Asset Purchase Agreement. Membership Interest Purchase Agreement On April 5, 2018, ECS Acquisition Co. LLC, a Delaware limited liability company (the Purchaser) and a wholly-owned subsidiary of Netsmart, Change Healthcare Technologies, LLC, a Delaware limited liability company (CHT), and Change Healthcare Holdings, LLC, a Delaware limited liability company (CHC and, together with CHT, the Sellers), entered into a Membership Interest Purchase Agreement (the Purchase Agreement). Pursuant to, and subject to the terms and conditions of, the Purchase Agreement, Purchaser will purchase (the Acquisition) all issued and outstanding membership interests of Barista Operations, LLC, a Delaware limited liability company, which entity, as of the closing of the Acquisition, will own and operate the extended care solutions business of Sellers and their subsidiaries providing information technology solutions and services to the Care at Home industry, which comprises the Extended Care Solutions business of McKesson Technology Solutions that was contributed to CHC by McKesson Corporation effective March 1, 2017. The purchase price for the Acquisition will be $167.5 million, subject to adjustments for net working capital, and will be funded with borrowings under the Netsmart Credit Agreements. $2.5 million of the purchase price will be deposited into escrow at the closing of the Acquisition and will be subject to release to the Sellers or to the Purchaser as described below. Completion of the Acquisition is subject to customary conditions, including (i) the expiration or termination of the waiting period applicable to consummation of the Acquisition under the Hart-Scott-Rodino Antitrust Improvements Act of 1975, as amended, (ii) the absence of any law, order or injunction prohibiting the closing of the Acquisition, (iii) the accuracy of the other party’s representations and warranties (subject to customary materiality qualifiers), (iv) each party having performed in all material respects all of its obligations under the Purchase Agreement and (v) no occurrence of a Material Adverse Effect (as defined in the Purchase Agreement) since the execution of the Purchase Agreement. The Purchase Agreement may be terminated by Purchaser or Sellers under certain circumstances, including if the Acquisition is not consummated by October 5, 2018 (provided that, if the Acquisition has not closed as of such date solely because of the failure to satisfy the condition described in clause (i) or clause (ii) above, such date may be extended by either party until January 7, 2019). There is no financing condition to the consummation of the Acquisition. The Purchase Agreement also contemplates that CHC will provide certain transition services to Purchaser pursuant to a transition services agreement. Additionally, the Purchase Agreement contemplates that CHC and Netsmart Technologies will negotiate in good faith and use commercially reasonable efforts to enter into certain commercial arrangements pursuant to which, among other things, Netsmart Technologies will market and sell certain products of CHC. The $2.5 million of the purchase price deposited in escrow at closing will be distributed to CHC and the Purchaser based on the achievement of certain revenue thresholds. Agreement to Acquire HealthGrid On April 27, 2018, Allscripts, Healthcare LLC and FollowMyHealth Merger Sub, Inc., a Delaware corporation (“ Merger Sub Merger Agreement Health Grid Merger

Basis of Presentation and Sig23

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2018 and 2017 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2017 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Change in Presentation	Change in Presentation During the first quarter of 2018, we changed the presentation of certain bundled revenue streams. Such revenue was previously included as part of software delivery, support and maintenance revenue. Under the new presentation, such revenue is included as part of client services revenue. The revenue previously reported for the first quarter of 2017 has been recast to match the new presentation by reducing software delivery, support and maintenance and increasing client services by $4.3 million.
Significant Accounting Policies	Significant Accounting Policies We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASC 606”) effective on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. There have been no other changes to our significant accounting policies from those disclosed in our Form 10-K.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In January 2016, the FASB issued Accounting Standards Update No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities” In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “ Leases (Topic 842) In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2018
Schedule of Supplemental Proforma Results	The revenue and earnings of the EIS Business, since October 2, 2017, and NantHealth, since August 25, 2017, are included in our consolidated statement of operations for the three months ended March 31, 2018. The below supplemental pro forma revenue and net loss of the combined entity is presented as if both acquisitions had occurred on January 1, 2016. (In thousands, except per share amounts) Three Months Ended March 31, 2017 Supplemental pro forma data for combined entity: Revenue $ 520,810 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (17,572 ) Loss per share, basic and diluted $ (0.10 )
Practice Fusion, Inc. [Member]
Schedule of Consideration Funded by Sources of Funds	The consideration paid for Practice Fusion is shown below: (In thousands) Aggregate purchase price $ 100,000 Add: Net working capital surplus 469 Less: Adjustment for assumed indebtedness (1,684 ) Add: Closing cash 14,951 Total consideration paid for Practice Fusion $ 113,736
Assets Acquired and Liabilities Assumed	The allocation of the fair value of the consideration transferred as of the acquisition date of February 13, 2018 is shown in the table below. (In thousands) Cash and cash equivalents $ 14,951 Accounts receivable, net 13,397 Prepaid expenses and other current assets 809 Fixed assets 1,764 Intangible assets 67,200 Goodwill 34,739 Other assets 43 Accounts payable and accrued expenses (7,620 ) Deferred revenue (2,400 ) Long-term deferred tax liability (8,332 ) Other liabilities (815 ) Net assets acquired $ 113,736
Acquired Intangible Assets Amortization	The following table summarizes the preliminary fair values of the identifiable intangible assets and their estimated useful lives: Useful Life Fair Value Description (In years) (In thousands) Customer Relationships - Physician Practices 15 $ 28,700 Customer Relationships - Pharmaceutical Partners 20 19,800 Technology 8 14,800 Tradenames 10 3,900 $ 67,200

Fair Value Measurements and L25

Fair Value Measurements and Long-term Investments (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet March 31, 2018 December 31, 2017 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 1.25% Call Option Other assets $ 0 $ 0 $ 25,410 $ 25,410 $ 0 $ 0 $ 46,578 $ 46,578 1.25% Embedded cash conversion option Other liabilities 0 0 (26,446 ) (26,446 ) 0 0 (47,777 ) (47,777 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 503 0 503 0 1,136 0 1,136 Total $ 0 $ 503 $ (1,036 ) $ (533 ) $ 0 $ 1,136 $ (1,199 ) $ (63 )
Summary of Long-term Equity Investments Included in Other Assets	The following table summarizes our long-term equity investments which are included in other assets in the accompanying consolidated balance sheets: Number of Investees Original Carrying Value at (In thousands, except # of investees) at March 31, 2018 Investment March 31, 2018 December 31, 2017 Equity method investments (1) 4 $ 5,658 $ 7,197 $ 3,258 Cost method investments 7 32,784 21,820 26,755 Total equity investments 11 $ 38,442 $ 29,017 $ 30,013 _________________________________ (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Stock-Based Compensation Expense (Benefit)	Three Months Ended March 31, (In thousands) 2018 2017 Cost of revenue: Software delivery, support and maintenance $ 616 $ 1,125 Client services 1,436 1,572 Total cost of revenue 2,052 2,697 Selling, general and administrative expenses 7,245 3,550 Research and development 2,841 2,589 Total stock-based compensation expense $ 12,138 $ 8,836
Stock-Based Awards Granted	We granted stock-based awards as follows: Three Months Ended March 31, 2018 Weighted-Average Grant Date (In thousands, except per share amounts) Shares Fair Value Service-based restricted stock units 1,300 $ 14.20 Performance-based restricted stock units with a service condition 524 $ 15.74 Market-based restricted stock units with a service condition 0 $ 0.00 1,824 $ 14.64

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Three Months Ended March 31, (In thousands, except per share amounts) 2018 2017 Basic Loss per Common Share: (Loss) income from continuing operations, net of tax $ (32,930 ) $ (8,565 ) Less: Net loss (income) attributable to non-controlling interests 790 (453 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (12,149 ) (10,962 ) Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (44,289 ) $ (19,980 ) Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders 4,415 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (39,874 ) $ (19,980 ) Weighted-average common shares outstanding 179,882 180,767 Basic Loss from continuing operations per Common Share $ (0.25 ) $ (0.11 ) Basic Income from discontinued operations per Common Share 0.03 0.00 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ (0.22 ) $ (0.11 ) Diluted Loss per Common Share: (Loss) income from continuing operations, net of tax $ (32,930 ) $ (8,565 ) Less: Net loss (income) attributable to non-controlling interests 790 (453 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart (12,149 ) (10,962 ) Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (44,289 ) $ (19,980 ) Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders 4,415 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (39,874 ) $ (19,980 ) Weighted-average common shares outstanding 179,882 180,767 Plus: Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 Weighted-average common shares outstanding assuming dilution 179,882 180,767 Diluted Loss from continuing operations per Common Share $ (0.25 ) $ (0.11 ) Diluted Income from discontinued operations per Common Share 0.03 0.00 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share $ (0.22 ) $ (0.11 )
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended March 31, (In thousands) 2018 2017 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 23,208 26,689

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: March 31, 2018 December 31, 2017 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 693,844 $ (419,081 ) $ 274,763 $ 695,354 $ (405,114 ) $ 290,240 Customer contracts and relationships 948,703 (475,407 ) 473,296 922,492 (464,860 ) 457,632 Total $ 1,642,547 $ (894,488 ) $ 748,059 $ 1,617,846 $ (869,974 ) $ 747,872 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 79,000 Goodwill 2,051,437 2,004,953 Total $ 2,130,437 $ 2,083,953
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2018 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2017 $ 861,615 $ 431,132 $ 712,206 $ 2,004,953 Additions arising from business acquisitions: Practice Fusion acquisition 34,739 0 0 34,739 Other acquisitions 4,829 0 1,374 6,203 Total arising from business acquisitions 39,568 0 1,374 40,942 Increases (decreases) due to measurement period adjustments: NantHealth provider/patient solutions business 0 117 0 117 Enterprise Information Solutions business 9,204 28,454 0 37,658 Other measurement period adjustments (205 ) 0 0 (205 ) Total increases (decreases) due to measurement period adjustments: 8,999 28,571 0 37,570 Total additions to goodwill 48,567 28,571 1,374 78,512 Divestitures (30,105 ) (2,198 ) 0 (32,303 ) Foreign exchange translation 275 0 0 275 Balance as of March 31, 2018 $ 880,352 $ 457,505 $ 713,580 2,051,437

Revenue from Contracts with C29

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2018
Revenue Recognized Related To Various Performance Obligations And Elected Accounting Expedients	The breakdown of revenue recognized related to various performance obligations and elected accounting expedients is presented in the table below: (In thousands) Three Months Ended March 31, 2018 Revenue related to deferred revenue balance at beginning of period $ 204,297 Revenue related to new performance obligations satisfied during the period 257,222 Revenue recognized under "right-to-invoice" expedient 49,638 Reimbursed travel expenses, shipping and other revenue 2,769 Total revenue $ 513,926
Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments	The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments: Three Months Ended March 31, (In thousands) 2018 2017 Revenue: Software delivery, support and maintenance Recurring revenue $ 294,455 $ 227,450 Non-recurring revenue 35,311 40,738 Total software delivery, support and maintenance 329,766 268,188 Client services Recurring revenue $ 122,474 $ 101,779 Non-recurring revenue 61,686 43,508 Total client services 184,160 145,287 Total revenue $ 513,926 $ 413,475 Three Months Ended March 31, 2018 (In thousands) Clinical and Financial Solutions Population Health Netsmart Unallocated Discontinued Operations Total Software delivery, support and maintenance $ 230,557 $ 61,198 $ 49,245 $ 1,165 $ (12,399 ) $ 329,766 Client services 143,422 8,507 33,241 (3,113 ) 2,103 184,160 Total revenue $ 373,979 $ 69,705 $ 82,486 $ (1,948 ) $ (10,296 ) $ 513,926 Three Months Ended March 31, 2017 (In thousands) Clinical and Financial Solutions Population Health Netsmart Unallocated Discontinued Operations Total Software delivery, support and maintenance $ 178,330 $ 39,689 $ 46,496 $ 3,673 $ 0 $ 268,188 Client services 117,850 3,741 26,511 (2,815 ) 0 145,287 Total revenue $ 296,180 $ 43,430 $ 73,007 $ 858 $ 0 $ 413,475
ASC 606
Impact of Adoption of ASC 606 on Financial Statements	The following adjustments were made to balances previously reported on the condensed consolidated balance sheet as of December 31, 2017: As Reported Adjustments Adjusted (In thousands, except per share amounts) December 31, 2017 due to ASC 606 January 1, 2018 Accounts receivable, net $ 567,873 $ (32,529 ) $ 535,344 Contract assets 0 76,509 76,509 Prepaid expenses and other current assets 115,463 11,646 127,109 Deferred revenue, current 546,830 (7,453 ) 539,377 Deferred revenue, long-term 24,047 0 24,047 Deferred taxes, net 93,643 16,478 110,121 Accumulated deficit (338,150 ) 46,601 (291,549 ) The following tables compare the reported consolidated balance sheet and statement of operations as of and for the three months ended March 31, 2018, to the pro-forma amounts assuming the previous guidance of ASC 605 had been in effect: March 31, 2018 (In thousands, except per share amounts) As reported under ASC 606 Adjustments due to ASC 606 Pro forma under ASC 605 Accounts receivable, net $ 495,695 $ 78,302 $ 573,997 Contract assets 45,068 (45,068 ) 0 Prepaid expenses and other current assets 130,051 33 130,084 Contract assets - long-term 40,486 (40,486 ) 0 Deferred revenue, current 540,289 (972 ) 539,317 Deferred taxes, net 117,061 (1,629 ) 115,432 Accumulated deficit (319,271 ) (4,618 ) (323,889 ) Three Months Ended March 31, 2018 (In thousands, except per share amounts) As reported under ASC 606 Adjustments due to ASC 606 Pro forma under ASC 605 Software delivery, support and maintenance $ 329,766 $ (5,028 ) $ 324,738 Client services 184,160 (1,066 ) 183,094 Gross profit 220,975 (6,279 ) 214,696 Selling, general and administrative expenses 143,070 (218 ) 142,852 Loss from operations (4,320 ) (6,061 ) (10,381 ) Loss from continuing operations before income taxes (35,844 ) (6,247 ) (42,091 ) Income tax benefit 2,914 1,629 4,543 Net loss (28,515 ) (4,618 ) (33,133 ) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (39,874 ) (4,618 ) $ (44,492 ) Loss per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (0.22 ) (0.03 ) $ (0.25 ) Loss per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (0.22 ) (0.03 ) $ (0.25 )

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2018
Debt Instrument [Line Items]
Debt Outstanding Excluding Capital Leases	Debt outstanding, excluding capital leases, consists of the following: March 31, 2018 December 31, 2017 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 32,571 $ 312,429 $ 345,000 $ 35,978 $ 309,022 Senior Secured Credit Facility 778,750 7,371 771,379 628,750 3,360 625,390 Netsmart Non-Recourse Debt: First Lien Term Loan 478,099 10,420 467,679 479,316 10,950 468,366 Second Lien Term Loan 167,000 7,047 159,953 167,000 7,418 159,582 Total debt $ 1,768,849 $ 57,409 $ 1,711,440 $ 1,620,066 $ 57,706 $ 1,562,360 Less: Debt payable within one year - excluding Netsmart 20,000 497 19,503 28,125 438 27,687 Less: Debt payable within one year - Netsmart 4,866 2,106 2,760 4,866 2,111 2,755 Total long-term debt, less current maturities $ 1,743,983 $ 54,806 $ 1,689,177 $ 1,587,075 $ 55,157 $ 1,531,918
Interest Expense	Interest expense consists of the following: Three Months Ended March 31, (In thousands) 2018 2017 Interest expense $ 7,938 $ 4,834 Amortization of discounts and debt issuance costs 3,756 3,581 Netsmart: Interest expense (1) 12,451 10,917 Amortization of discounts and debt issuance costs 901 848 Total interest expense $ 25,046 $ 20,180 (1) Includes interest expense related to capital leases.
Summary of Future Debt Payment Obligations	The following table summarizes future debt payment obligations as of March 31, 2018: (In thousands) Total Remainder of 2018 2019 2020 2021 2022 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 345,000 $ 0 $ 0 $ 0 Term Loan 400,000 15,000 20,000 27,500 30,000 37,500 270,000 Revolving Facility (2) 378,750 0 0 0 0 0 378,750 Netsmart Non-Recourse Debt (2) First Lien Term Loan (3) 478,099 3,650 4,866 4,866 4,866 4,866 454,985 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Total debt $ 1,768,849 $ 18,650 $ 24,866 $ 377,366 $ 34,866 $ 42,366 $ 1,270,735 (1) (2) (3)
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest Expense Related to 1.25% Notes	Interest expense related to the 1.25% Notes, included in the table above, consists of the following: Three Months Ended March 31, (In thousands) 2018 2017 Coupon interest at 1.25% $ 1,078 $ 1,078 Amortization of discounts and debt issuance costs 3,407 3,246 Total interest expense related to the 1.25% Notes $ 4,485 $ 4,324

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Effective Tax Rates	Three Months Ended March 31, (In thousands) 2018 2017 Loss from continuing operations before income taxes $ (35,844 ) $ (8,393 ) Income tax benefit (provision) $ 2,914 $ (172 ) Effective tax rate 8.1 % (2.0 %)

Derivative Financial Instrume32

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2018
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: March 31, 2018 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 503 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 25,410 N/A 1.25% Embedded cash conversion option N/A Other liabilities 26,446 Total derivatives $ 25,913 $ 26,446 December 31, 2017 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,136 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 46,578 N/A 1.25% Embedded cash conversion option N/A Other liabilities 47,777 Total derivatives $ 47,714 $ 47,777 N/A – We define “N/A” as disclosure not being applicable
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended March 31, 2018 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended March 31, 2018 Foreign exchange contracts $ (78 ) Cost of Revenue $ 189 Selling, general and administrative expenses 144 Research and development $ 222 Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended March 31, 2017 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended March 31, 2017 Foreign exchange contracts $ 1,873 Cost of Revenue $ 178 Selling, general and administrative expenses 137 Research and development $ 210
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option	The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended March 31, (In thousands) 2018 2017 1.25% Call Option $ (21,168 ) $ 17,605 1.25% Embedded cash conversion option 21,331 (17,903 ) Net (loss) gain included in other income, net $ 163 $ (298 )

Other Comprehensive Income (Tab

Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2017 (1) $ (2,676 ) $ 691 $ (1,985 ) Other comprehensive income (loss) before reclassifications 123 (58 ) 65 Net losses (gains) reclassified from accumulated other comprehensive loss 0 (261 ) (261 ) Net other comprehensive income 123 (319 ) (196 ) Balance as of March 31, 2018 (2) $ (2,553 ) $ 372 $ (2,181 ) ______________________________________________________ (1) Net of taxes of $445 thousand for unrealized net gains on foreign exchange contract derivatives. (2) Net of taxes of $131 thousand for unrealized net gains on foreign exchange contract derivatives. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Available for Sale Securities (1) Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2016 (2) $ (6,028 ) $ (56,420 ) $ 619 $ (61,829 ) Other comprehensive (loss) income before reclassifications 1,515 (74,701 ) 1,146 (72,040 ) Net losses reclassified from accumulated other comprehensive loss 0 0 (320 ) (320 ) Net other comprehensive (loss) income 1,515 (74,701 ) 826 (72,360 ) Balance as of March 31, 2017 (3) $ (4,513 ) $ (131,121 ) $ 1,445 $ (134,189 ) ____________________________________________________________________________ (1) Majority of unrealized loss relates to decline in fair value of NantHealth common stock. (2) Net of taxes of $402 thousand for unrealized net gains on foreign exchange contract derivatives and $61 thousand for unrealized net gains on available for sale securities. ( 3 )
Income Tax Effects Related to Components of Other Comprehensive Income (Loss)	The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended March 31, 2018 2017 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 123 $ 0 $ 123 $ 1,515 $ 0 $ 1,515 Available for sale securities: Net loss arising during the period 0 0 0 (74,702 ) 1 (74,701 ) Net loss reclassified into income 0 0 0 0 0 0 Net change in unrealized gains (losses) on available for sale securities 0 0 0 (74,702 ) 1 (74,701 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period (78 ) 20 (58 ) 1,873 (727 ) 1,146 Net (gains) losses reclassified into income (1) (555 ) 294 (261 ) (525 ) 205 (320 ) Net change in unrealized (losses) gains on foreign exchange contracts (633 ) 314 (319 ) 1,348 (522 ) 826 Net (loss) gain on cash flow hedges (633 ) 314 (319 ) 1,348 (522 ) 826 Other comprehensive income (loss) $ (510 ) $ 314 $ (196 ) $ (71,839 ) $ (521 ) $ (72,360 ) ____________________________________________ (1) Tax effects for the three months ended March 31, 2018 include $149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income at December 31, 2017.

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2018
Discontinued Operations And Disposal Groups [Abstract]
Summary of Discontinued Operations in Financial Statements	The following table summarizes the major classes of assets and liabilities of the discontinued operation, as reported on the consolidated balance sheet as of March 31, 2018: (In thousands) March 31, 2018 December 31, 2017 Carrying amounts of major classes of assets included as part of discontinued operations: Accounts receivable, net $ 2,265 $ 8,196 Prepaid expenses and other current assets 2,680 3,080 Total assets attributable to discontinued operations $ 4,945 $ 11,276 Carrying amounts of major classes of liabilities included as part of discontinued operations: Accounts payable $ 104 $ 114 Accrued expenses 6,150 5,599 Accrued compensation and benefits 8,022 7,728 Deferred revenue 0 7,241 Other classes of liabilities that are not major 0 676 Total liabilities attributable to discontinued operations $ 14,276 $ 21,358 The following table summarizes the major classes of line items constituting income (loss) of the discontinued operation, as reported in the consolidated statements of operations for the three months ended March 31, 2018: Three months ended (In thousands) March 31, 2018 Major classes of line items constituting pretax profit (loss) of discontinued operations Revenue: Software delivery, support and maintenance $ 9,804 Client services 492 Total revenue 10,296 Cost of revenue: Software delivery, support and maintenance 2,463 Client services 743 Total cost of revenue 3,206 Gross profit 7,090 Selling, general and administrative expenses 0 Research and development 1,124 Income from discontinued operations before income taxes 5,966 Income tax provision (1,551 ) Income from discontinued operations, net of tax $ 4,415

Business Segments (Tables)

Business Segments (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Three Months Ended March 31, (In thousands) 2018 2017 Revenue: Clinical and Financial Solutions $ 373,979 $ 296,180 Population Health 69,705 43,429 Netsmart 82,486 73,007 Unallocated Amounts (1,948 ) 859 Discontinued Operations (10,296 ) 0 Total revenue $ 513,926 $ 413,475 Gross Profit: Clinical and Financial Solutions $ 154,286 $ 119,261 Population Health 53,371 35,845 Netsmart 36,301 34,574 Unallocated Amounts (15,893 ) (11,028 ) Discontinued Operations (7,090 ) 0 Total gross profit $ 220,975 $ 178,652 Income (loss) from operations: Clinical and Financial Solutions $ 70,742 $ 53,582 Population Health 36,434 28,468 Netsmart 2,313 8,929 Unallocated Amounts (107,843 ) (79,716 ) Discontinued Operations (5,966 ) 0 Total income from operations $ (4,320 ) $ 11,263

Supplemental Disclosures (Table

Supplemental Disclosures (Tables)	3 Months Ended
	Mar. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	The majority of the restricted cash balance as of March 31, 2018 represents Netsmart’s cash deposits to maintain two letters of credit with a financial institution related to customer agreements and an escrow fund related to a previous acquisition associated with the acquired EIS Business. Three Months Ended March 31, (In thousands) 2018 2017 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 135,003 $ 104,391 Restricted cash 8,769 - Total cash, cash equivalents and restricted cash $ 143,772 $ 104,391 Supplemental non-cash information: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart $ 12,149 $ 10,962 Obligations incurred to purchase capitalized software or enter into capital leases $ 9,786 $ 1,407 Contribution of assets in exchange for equity interest $ 4,000 $ 0

Basis of Presentation and Sig37

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Basis Of Presentation And Significant Accounting Policies [Line Items]
Software delivery, support and maintenance	$ 329,766	$ 268,188
Client services	184,160	$ 145,287
Adjustment [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Software delivery, support and maintenance	(4,300)
Client services	$ 4,300

Business Combinations - Acquisi

Business Combinations - Acquisition of Practice Fusion, Inc - Additional Information (Detail) - USD ($)	Feb. 13, 2018	Mar. 31, 2018
Business Acquisition [Line Items]
Goodwill expected to be tax deductible		$ 0
Practice Fusion, Inc. [Member]
Business Acquisition [Line Items]
Date of acquisition	Feb. 13, 2018
Business combination, aggregate consideration	$ 113,736,000
Practice Fusion, Inc. [Member] | Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition-related costs		$ 500,000

Schedule of Consideration Trans

Schedule of Consideration Transaction (Detail) - Practice Fusion, Inc. [Member] $ in Thousands	Feb. 13, 2018USD ($)
Business Acquisition [Line Items]
Aggregate purchase price	$ 100,000
Add: Net working capital surplus	469
Less: Adjustment for assumed indebtedness	(1,684)
Add: Closing cash	14,951
Business combination, aggregate consideration	$ 113,736

Assets Acquired and Liabilities

Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Feb. 13, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	$ 2,051,437		$ 2,004,953
Practice Fusion, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		$ 14,951
Accounts receivable, net		13,397
Prepaid expenses and other current assets		809
Fixed assets		1,764
Intangible assets		67,200
Goodwill		34,739
Other assets		43
Accounts payable and accrued expenses		(7,620)
Deferred revenue		(2,400)
Long-term deferred tax liability		(8,332)
Other liabilities		(815)
Net assets acquired		$ 113,736

Acquired Intangible Assets Amor

Acquired Intangible Assets Amortization (Detail) - Practice Fusion, Inc. [Member] $ in Thousands	Feb. 13, 2018USD ($)
Business Acquisition [Line Items]
Intangible assets	$ 67,200
Customer Relationships - Physician Practices [Member]
Business Acquisition [Line Items]
Description	15 years
Customer Relationships	$ 28,700
Customer Relationships - Pharmaceutical Partners [Member]
Business Acquisition [Line Items]
Description	20 years
Customer Relationships	$ 19,800
Technology [Member]
Business Acquisition [Line Items]
Description	8 years
Customer Relationships	$ 14,800
Tradenames [Member]
Business Acquisition [Line Items]
Description	10 years
Customer Relationships	$ 3,900

Business Combinations - Other A

Business Combinations - Other Acquisitions and Divestiture - Additional Information (Detail) - USD ($)	Feb. 06, 2018	Jan. 31, 2018	Oct. 02, 2017	Apr. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Business Acquisition [Line Items]
Cash paid for business acquisitions					$ 109,020,000	$ 3,975,000
Goodwill					2,051,437,000		$ 2,004,953,000
Goodwill expected to be tax deductible					0
Equity method investments					$ 7,197,000		$ 3,258,000
Unit Purchase Agreement [Member]
Business Acquisition [Line Items]
Goodwill		$ 1,400,000
Date of acquisition agreement date		Jan. 31, 2018
Business combination, aggregate consideration		$ 5,400,000
Consideration paid in cash		$ 2,000,000
Ownership percentage acquired		100.00%
Business combination consideration remaining amount payable		$ 3,600,000
Cloud-based Analytics Software Platform Provider [Member]
Business Acquisition [Line Items]
Date of acquisition	Feb. 6, 2018
Cash paid for business acquisitions	$ 8,000,000
Goodwill	4,800,000
Accounts receivable, net	800,000
Liabilities assumed, account payable	200,000
Liabilities assumed, deferred revenue	600,000
Liabilities assumed, deferred tax liabilities net	1,100,000
Goodwill expected to be tax deductible	0
Cloud-based Analytics Software Platform Provider [Member] | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets	3,700,000
Description					8 years
Cloud-based Analytics Software Platform Provider [Member] | Customer Relationships
Business Acquisition [Line Items]
Intangible assets	$ 600,000
Description					1 year
EIS Business [Member]
Business Acquisition [Line Items]
Business combination, aggregate consideration			$ 185,000,000
Effective date of divestiture					March 15, 2018
Minority interest percentage					35.70%
Equity method investments					$ 4,000,000
EIS Business [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Business combination, aggregate consideration				$ 2,700,000
EIS Business [Member] | Other (Loss) Income [Member]
Business Acquisition [Line Items]
Loss on investment					$ 900,000

Business Combinations - Acqui43

Business Combinations - Acquisition of DeVero - Additional Information (Detail) - USD ($)	Jul. 17, 2017	Mar. 31, 2018	Mar. 31, 2017
Business Acquisition [Line Items]
Cash paid for business acquisitions		$ 109,020,000	$ 3,975,000
Netsmart [Member] | DeVero Inc [Member]
Business Acquisition [Line Items]
Date of acquisition	Jul. 17, 2017
Cash paid for business acquisitions	$ 50,500,000
Measurement period adjustments recorded		$ 0

Business Combinations - Acqui44

Business Combinations - Acquisition of the Patient/Provider Engagement Solutions Business from NantHealth, Inc. - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Business Acquisition [Line Items]
Goodwill Purchase Accounting Adjustments	$ 37,570
NantHealth, Inc. [Member]
Business Acquisition [Line Items]
Date of acquisition	Aug. 25, 2017
Goodwill Purchase Accounting Adjustments	$ 117

Business Combinations and Other

Business Combinations and Other Investments - Acquisition of the Enterprise Information Solutions Business from McKesson Corporation - Additional Information (Detail) $ in Thousands	Oct. 02, 2017USD ($)Subsidiary	Mar. 31, 2018USD ($)
Business Acquisition [Line Items]
Goodwill Purchase Accounting Adjustments		$ 37,570
EIS Business [Member]
Business Acquisition [Line Items]
Number of wholly owned subsidiaries in which outstanding equity interest acquired | Subsidiary	2
Business combination, aggregate consideration	$ 185,000
Goodwill Purchase Accounting Adjustments		37,658
Increase in deferred revenue		44,000
Increases in identified intangible assets		$ 6,600

Business Combinations - Formati

Business Combinations - Formation of Joint Business Entity and Acquisition of Netsmart, Inc - Additional Information (Detail) - USD ($) $ in Millions	Apr. 19, 2016	Mar. 31, 2018
Business Acquisition [Line Items]
Contribution and investment agreement date		Mar. 20, 2016
Homecare Business [Member]
Business Acquisition [Line Items]
Escrow deposit related to the integration of homecare business	$ 15	$ 9
Escrow deposit period	5 years
Netsmart [Member]
Business Acquisition [Line Items]
Netsmart transaction completion date		Apr. 19, 2016

Pro forma Results (Detail)

Pro forma Results (Detail) - Combined Entity [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / shares
Business Acquisition [Line Items]
Revenue	$ 520,810
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (17,572)
Loss per share, basic and diluted | $ / shares	$ (0.10)

Summary of Financial Assets and

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	$ 130,051	$ 115,463
Total	(533)	(63)
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	503	1,136
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(26,446)	(47,777)
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	25,410	46,578
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	0	0
Level 1 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 1 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	503	1,136
Level 2 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	503	1,136
Level 2 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	(1,036)	(1,199)
Level 3 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 3 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(26,446)	(47,777)
Level 3 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	$ 25,410	$ 46,578

Summary of Long-term Equity Inv

Summary of Long-term Equity Investments Included in Other Assets (Detail) $ in Thousands		3 Months Ended
		Mar. 31, 2018USD ($)Investment	Dec. 31, 2017USD ($)
Fair Value Disclosures [Abstract]
Equity method investments, Number of Investees | Investment	[1]	4
Cost method investments, Number of Investees | Investment		7
Total equity investments, Number of Investees | Investment		11
Equity method investments, Original Investment	[1]	$ 5,658
Cost method investments, Original Investment		32,784
Total equity investments, Original Investment		38,442
Equity method investments, Carrying Value		7,197	$ 3,258
Cost method investments, Carrying Value		21,820	26,755
Total equity investments, Carrying Value		$ 29,017	$ 30,013
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Fair Value Measurements and L50

Fair Value Measurements and Long-term Investments - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Non-cash impairment charge of investments	$ 5.5
Cost basis of cost-method equity investments	4.9
Cost basis of note receivable prior to impairment	$ 2.6
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended			12 Months Ended
	Mar. 31, 2018	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Nov. 17, 2016
Class Of Stock [Line Items]
Capitalized stock-based compensation costs	$ 0		$ 0
Stock options granted	0		0
Share issued, exercise of options and release of stock awards	1,300,000			1,300,000
Shares settled for tax withholding	609,000		494,000
Common stock repurchased, amount	$ 57,599,000		$ 0
Netsmart [Member]
Class Of Stock [Line Items]
Stock options granted	0
Stock based compensation expense (benefit)	$ 1,200		$ (3,500)
Liability for outstanding awards	$ 9,200,000
Estimated weighted average fair value, Black-Scholes-Merton option pricing model	$ 0.30				$ 0.54
November 2016 Stock Repurchase Program [Member]
Class Of Stock [Line Items]
Stock repurchase program, authorized amount						$ 200,000,000
Common stock repurchased, shares		4,100,000
Common stock repurchased, amount		$ 57,600,000
Approximate value of common stock shares yet to be purchased under the stock repurchase program		$ 106,400,000

Stock-Based Compensation Expens

Stock-Based Compensation Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 12,138	$ 8,836
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	2,052	2,697
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	616	1,125
Cost of revenue [Member] | Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	1,436	1,572
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	7,245	3,550
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 2,841	$ 2,589

Stock-Based Awards Granted (Det

Stock-Based Awards Granted (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	1,824
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 14.64
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	1,300
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 14.20
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	524
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 15.74
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	0
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 0

Calculations of Earnings (Loss)

Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Basic Loss per Common Share:
(Loss) income from continuing operations, net of tax	$ (32,930)	$ (8,565)
Less: Net loss (income) attributable to non-controlling interests	790	(453)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(12,149)	(10,962)
Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	(44,289)	(19,980)
Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	4,415	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (39,874)	$ (19,980)
Weighted-average common shares outstanding	179,882	180,767
Continuing operations	$ (0.25)	$ (0.11)
Discontinued operations	0.03	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ (0.22)	$ (0.11)
Diluted Loss per Common Share:
(Loss) income from continuing operations, net of tax	$ (32,930)	$ (8,565)
Less: Net loss (income) attributable to non-controlling interests	790	(453)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(12,149)	(10,962)
Net loss from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	(44,289)	(19,980)
Net income from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	4,415	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (39,874)	$ (19,980)
Weighted-average common shares outstanding	179,882	180,767
Plus: Dilutive effect of stock options, restricted stock unit awards and warrants	0	0
Weighted-average common shares outstanding assuming dilution	179,882	180,767
Continuing operations	$ (0.25)	$ (0.11)
Discontinued operations	0.03	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ (0.22)	$ (0.11)

Anti-Dilutive Stock Options, Re

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	23,208	26,689

Goodwill and Intangible Asset56

Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,642,547	$ 1,617,846
Accumulated Amortization	(894,488)	(869,974)
Intangible Assets, Net	748,059	747,872
Registered trademarks	79,000	79,000
Goodwill	2,051,437	2,004,953
Total	2,130,437	2,083,953
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	693,844	695,354
Accumulated Amortization	(419,081)	(405,114)
Intangible Assets, Net	274,763	290,240
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	948,703	922,492
Accumulated Amortization	(475,407)	(464,860)
Intangible Assets, Net	$ 473,296	$ 457,632

Changes in Carrying Amount of G

Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Goodwill [Line Items]
Goodwill	$ 2,004,953
Additions arising from business acquisitions	40,942
Total increases (decreases) due to measurement period adjustments:	37,570
Total additions to goodwill	78,512
Divestitures	(32,303)
Foreign exchange translation	275
Goodwill, net	2,051,437
Practice Fusion, Inc. [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	34,739
Other [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	6,203
Total increases (decreases) due to measurement period adjustments:	(205)
NantHealth, Inc. [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	117
EIS Business [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	37,658
Clinical and Financial Solutions [Member]
Goodwill [Line Items]
Goodwill	861,615
Additions arising from business acquisitions	39,568
Total increases (decreases) due to measurement period adjustments:	8,999
Total additions to goodwill	48,567
Divestitures	(30,105)
Foreign exchange translation	275
Goodwill, net	880,352
Clinical and Financial Solutions [Member] | Practice Fusion, Inc. [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	34,739
Clinical and Financial Solutions [Member] | Other [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	4,829
Total increases (decreases) due to measurement period adjustments:	(205)
Clinical and Financial Solutions [Member] | NantHealth, Inc. [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	0
Clinical and Financial Solutions [Member] | EIS Business [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	9,204
Population Health [Member]
Goodwill [Line Items]
Goodwill	431,132
Additions arising from business acquisitions	0
Total increases (decreases) due to measurement period adjustments:	28,571
Total additions to goodwill	28,571
Divestitures	(2,198)
Foreign exchange translation	0
Goodwill, net	457,505
Population Health [Member] | Practice Fusion, Inc. [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	0
Population Health [Member] | Other [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	0
Total increases (decreases) due to measurement period adjustments:	0
Population Health [Member] | NantHealth, Inc. [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	117
Population Health [Member] | EIS Business [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	28,454
Netsmart [Member]
Goodwill [Line Items]
Goodwill	712,206
Additions arising from business acquisitions	1,374
Total increases (decreases) due to measurement period adjustments:	0
Total additions to goodwill	1,374
Divestitures	0
Foreign exchange translation	0
Goodwill, net	713,580
Netsmart [Member] | Practice Fusion, Inc. [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	0
Netsmart [Member] | Other [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	1,374
Total increases (decreases) due to measurement period adjustments:	0
Netsmart [Member] | NantHealth, Inc. [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	0
Netsmart [Member] | EIS Business [Member]
Goodwill [Line Items]
Total increases (decreases) due to measurement period adjustments:	$ 0

Goodwill and Intangible Asset58

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	Jan. 02, 2018	Mar. 31, 2018	Feb. 13, 2018	Feb. 06, 2018	Dec. 31, 2017
Schedule Of Goodwill And Intangible Assets [Line Items]
Accumulated impairment losses associated with goodwill		$ 0			$ 0
Additions		40,942,000
Total increases (decreases) due to measurement period adjustments:		37,570,000
Goodwill reduction due to divestiture		32,303,000
Goodwill, impairments recorded	$ 0
Goodwill		$ 2,051,437,000			$ 2,004,953,000
Hospital and Health Systems [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Percentage of excess of fair value over carrying value		10.00%
Goodwill		$ 511,200,000
EIS Business [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Goodwill reduction due to divestiture		2,200,000
One Content Business [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Goodwill reduction due to divestiture		30,100,000
Practice Fusion, Inc. [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Additions		34,739,000
Goodwill			$ 34,739,000
Cloud-based Analytics Software Platform Provider [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Additions		4,800,000
Goodwill				$ 4,800,000
Provider of Billing Solutions [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Additions		1,400,000
EIS Business [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Total increases (decreases) due to measurement period adjustments:		$ 37,658,000

Revenue from Contracts with C59

Revenue from Contracts with Customers - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)Revenue_Stream
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Number of primary revenue streams | Revenue_Stream	2
Capitalized Contract Cost, Gross	$ 27.4
Capitalized Contract Cost Amortization	8.2
Total backlog	$ 4,700
Total backlog, percentage, year one	36.00%
Total backlog, percentage after year two	64.00%
Perpetual Software License Contracts [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Description of payment terms	The majority of our contracts contain provisions that require customer payment no later than one year from the transfer of control of the related performance obligation
Interest income recognized	$ 0.2
Selling, General and Administrative Expenses [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost Amortization	8.1
Cost of revenue [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost Amortization	$ 0.1
Minimum [Member] | Perpetual Software License Contracts [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Payments range	2 years
Maximum [Member] | Perpetual Software License Contracts [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Payments range	10 years
ASC 606
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Deferred costs for fulfilment of contract	$ 8.6
ASC 606 | Minimum [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized cost, amortization period	2 years
ASC 606 | Maximum [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized cost, amortization period	9 years

Revenue from Contracts with C60

Revenue from Contracts with Customers - Impact of Adoption on Previously Reported Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	$ 495,695		$ 567,873
Contract assets	45,068		0
Prepaid expenses and other current assets	130,051		115,463
Deferred revenue	540,289		546,830
Deferred revenue	25,876		24,047
Deferred taxes, net	117,061		93,643
Accumulated deficit	(319,271)		$ (338,150)
ASC 606
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net		$ 535,344
Contract assets		76,509
Prepaid expenses and other current assets		127,109
Deferred revenue		539,377
Deferred revenue		24,047
Deferred taxes, net		110,121
Accumulated deficit		(291,549)
ASC 606 | Adjustments Due to ASC 606 [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	78,302	(32,529)
Contract assets	(45,068)	76,509
Prepaid expenses and other current assets	33	11,646
Deferred revenue	(972)	(7,453)
Deferred revenue		0
Deferred taxes, net		16,478
Accumulated deficit	$ (4,618)	$ 46,601

Revenue from Contracts with C61

Revenue from Contracts with Customers - Schedule of Comparison Between Reported Statements to Pro-forma Amounts in Effect of Previous Guidance - Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accounts receivable, net	$ 495,695		$ 567,873
Contract assets	45,068		0
Prepaid expenses and other current assets	130,051		115,463
Contract assets - long-term	40,486		0
Deferred revenue	540,289		546,830
Deferred taxes, net	117,061
Accumulated deficit	(319,271)		$ (338,150)
ASC 606
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accounts receivable, net		$ 535,344
Contract assets		76,509
Prepaid expenses and other current assets		127,109
Deferred revenue		539,377
Accumulated deficit		(291,549)
ASC 606 | Adjustments Due to ASC 606 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accounts receivable, net	78,302	(32,529)
Contract assets	(45,068)	76,509
Prepaid expenses and other current assets	33	11,646
Contract assets - long-term	(40,486)
Deferred revenue	(972)	(7,453)
Deferred taxes, net	(1,629)
Accumulated deficit	(4,618)	$ 46,601
Pro forma Under ASC 605 [Member] | ASC 606
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Accounts receivable, net	573,997
Contract assets	0
Prepaid expenses and other current assets	130,084
Contract assets - long-term	0
Deferred revenue	539,317
Deferred taxes, net	115,432
Accumulated deficit	$ (323,889)

Revenue from Contracts with C62

Revenue from Contracts with Customers - Schedule of Comparison Between Reported Statements to Pro-forma Amounts in Effect of Previous Guidance - Statement of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Software delivery, support and maintenance	$ 329,766	$ 268,188
Client services	184,160	145,287
Gross profit	220,975	178,652
Selling, general and administrative expenses	143,070
Loss from operations	(4,320)	11,263
Loss from continuing operations before income taxes	(35,844)	(8,393)
Income tax benefit	2,914	(172)
Net loss	(28,515)	(8,565)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (39,874)	$ (19,980)
Loss per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.22)	$ (0.11)
Loss per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.22)	$ (0.11)
ASC 606 | Adjustments Due to ASC 606 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Software delivery, support and maintenance	$ (5,028)
Client services	(1,066)
Gross profit	(6,279)
Selling, general and administrative expenses	(218)
Loss from operations	(6,061)
Loss from continuing operations before income taxes	(6,247)
Income tax benefit	1,629
Net loss	(4,618)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (4,618)
Loss per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.03)
Loss per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.03)
Pro forma Under ASC 605 [Member] | ASC 606
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Software delivery, support and maintenance	$ 324,738
Client services	183,094
Gross profit	214,696
Selling, general and administrative expenses	142,852
Loss from operations	(10,381)
Loss from continuing operations before income taxes	(42,091)
Income tax benefit	4,543
Net loss	(33,133)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (44,492)
Loss per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.25)
Loss per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.25)

Revenue from Contract with Cust

Revenue from Contract with Customer - Summary of Revenue Regognized Related to Various Performance Obligations and Elected accounting Expedients (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Revenue From Contract With Customer [Abstract]
Revenue related to deferred revenue balance at beginning of period	$ 204,297
Revenue related to new performance obligations satisfied during the period	257,222
Revenue recognized under "right-to-invoice" expedient	49,638
Reimbursed travel expenses, shipping and other revenue	2,769
Total revenue	$ 513,926

Revenue from Contracts with C64

Revenue from Contracts with Customers - Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disaggregation Of Revenue [Line Items]
Total revenue	$ 513,926	$ 413,475
Discontinued Operations [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	(10,296)	0
Unallocated [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	(1,948)	858
Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	373,979	296,180
Population Health [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	69,705	43,430
Netsmart [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	82,486	73,007
Software delivery, Support and Maintenance [Member]
Disaggregation Of Revenue [Line Items]
Recurring revenue	294,455	227,450
Non-recurring revenue	35,311	40,738
Total revenue	329,766	268,188
Software delivery, Support and Maintenance [Member] | Discontinued Operations [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	(12,399)	0
Software delivery, Support and Maintenance [Member] | Unallocated [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1,165	3,673
Software delivery, Support and Maintenance [Member] | Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	230,557	178,330
Software delivery, Support and Maintenance [Member] | Population Health [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	61,198	39,689
Software delivery, Support and Maintenance [Member] | Netsmart [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	49,245	46,496
Client services [Member]
Disaggregation Of Revenue [Line Items]
Recurring revenue	122,474	101,779
Non-recurring revenue	61,686	43,508
Total revenue	184,160	145,287
Client services [Member] | Discontinued Operations [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	2,103	0
Client services [Member] | Unallocated [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	(3,113)	(2,815)
Client services [Member] | Clinical and Financial Solutions [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	143,422	117,850
Client services [Member] | Population Health [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	8,507	3,741
Client services [Member] | Netsmart [Member] | Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 33,241	$ 26,511

Debt Outstanding Excluding Capi

Debt Outstanding Excluding Capital Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2018		Dec. 31, 2017
Debt Instrument [Line Items]
Principal Balance	$ 1,768,849		$ 1,620,066
Unamortized Discount and Debt Issuance Costs	57,409		57,706
Net Carrying Amount	1,711,440		1,562,360
Principal Balance, Current	20,000		28,125
Unamortized Discount and Debt Issuance Costs, Current	497		438
Net Carrying Amount, Current	19,503		27,687
Principal Balance, Noncurrent	1,743,983		1,587,075
Unamortized Discount and Debt Issuance Costs, Noncurrent	54,806		55,157
Net Carrying Amount, Noncurrent	1,689,177		1,531,918
Netsmart [Member]
Debt Instrument [Line Items]
Principal Balance, Current	4,866		4,866
Unamortized Discount and Debt Issuance Costs, Current	2,106		2,111
Net Carrying Amount, Current	2,760		2,755
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	345,000	[1]	345,000
Unamortized Discount and Debt Issuance Costs	32,571		35,978
Net Carrying Amount	312,429		309,022
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Principal Balance	778,750		628,750
Unamortized Discount and Debt Issuance Costs	7,371		3,360
Net Carrying Amount	771,379		625,390
Netsmart Non-Recourse Debt First Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	478,099		479,316
Unamortized Discount and Debt Issuance Costs	10,420		10,950
Net Carrying Amount	467,679		468,366
Netsmart Non-Recourse Debt Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	167,000		167,000
Unamortized Discount and Debt Issuance Costs	7,047		7,418
Net Carrying Amount	$ 159,953		$ 159,582
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Interest Expense (Detail)

Interest Expense (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2018	Mar. 31, 2017
Debt Instrument [Line Items]
Total interest expense		$ 25,046	$ 20,180
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense		7,938	4,834
Amortization of discounts and debt issuance costs		3,756	3,581
Netsmart [Member]
Debt Instrument [Line Items]
Amortization of discounts and debt issuance costs		901	848
Interest expense	[1]	$ 12,451	$ 10,917
[1]	Includes interest expense related to capital leases.

Interest Expense Related to 1.2

Interest Expense Related to 1.25% Notes (Detail) - 1.25% Cash Convertible Senior Notes [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Debt Instrument [Line Items]
Coupon interest at 1.25%	$ 1,078	$ 1,078
Amortization of discounts and debt issuance costs	3,407	3,246
Total interest expense related to the 1.25% Notes	$ 4,485	$ 4,324

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)		Feb. 15, 2018	Mar. 31, 2018		Dec. 31, 2017	Sep. 30, 2015
Debt Instrument [Line Items]
Debt instrument principal amount			$ 1,768,849,000		$ 1,620,066,000
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Initial margin for borrowings based on non-Eurocurrency rate		1.00%
Initial margin for borrowings based on Eurocurrency rate		2.00%
Debt instrument principal amount			378,800,000
Letters of credit outstanding			800,000
Credit facility, amount available			$ 520,400,000
Senior Secured Revolving Facility [Member] | United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage			3.88%
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 400,000,000
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 345,000,000	[1]	$ 345,000,000
Interest rate			1.25%
Netsmart First Lien Credit Agreement [Member] | Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 478,100,000
Netsmart Second Lien Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage			11.38%
Netsmart Second Lien Credit Agreement [Member] | Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 167,000,000
Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	[2]		$ 478,099,000
Debt instrument, interest rate, effective percentage			6.38%
LIBOR Rate [Member] | Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread			2.00%
Debt instrument variable rate			2.00%
LIBOR Rate [Member] | Netsmart Second Lien Credit Agreement [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread			9.50%
Debt instrument variable rate			9.50%
LIBOR Rate [Member] | Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread			4.50%
Debt instrument variable rate			4.50%
Letter of Credit [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance of letters of credit		$ 50,000,000
Line of Credit [Member]
Debt Instrument [Line Items]
Portion of facility available for issuance of swingline loans		10,000,000
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity		$ 900,000,000				$ 550,000,000
Senior secured credit facilities term, years		5 years
Credit facility, maximum borrowing capacity, foreign currencies		$ 100,000,000
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity		$ 400,000,000				$ 250,000,000
Senior secured credit facilities term, years		5 years
Line of credit facility, frequency of payments			The Term Loan is repayable in quarterly installments commencing on June 30, 2018.
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Aggregate amount of additional credit facilities authorized		$ 600,000,000	$ 300,000,000
Second Amended Credit Agreement [Member] | Base Rate [Member] | Senior Secured Revolving Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread		0.50%
Debt instrument variable rate		0.50%
Second Amended Credit Agreement [Member] | Base Rate [Member] | Senior Secured Revolving Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread		1.25%
Debt instrument variable rate		1.25%
Second Amended Credit Agreement [Member] | Eurocurrency Rate [Member] | Senior Secured Revolving Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread		1.50%
Debt instrument variable rate		1.50%
Second Amended Credit Agreement [Member] | Eurocurrency Rate [Member] | Senior Secured Revolving Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread		2.25%
Debt instrument variable rate		2.25%
2015 Credit Agreement [Member] | Base Rate [Member] | Senior Secured Revolving Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread			0.00%
Debt instrument variable rate			0.00%
2015 Credit Agreement [Member] | Base Rate [Member] | Senior Secured Revolving Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread			1.25%
Debt instrument variable rate			1.25%
2015 Credit Agreement [Member] | Eurocurrency Rate [Member] | Senior Secured Revolving Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread			1.00%
Debt instrument variable rate			1.00%
2015 Credit Agreement [Member] | Eurocurrency Rate [Member] | Senior Secured Revolving Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread			2.25%
Debt instrument variable rate			2.25%
Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 0
Letters of credit outstanding			$ 0
Debt instrument, interest rate, effective percentage			6.63%
Credit facility, amount available			$ 50,000,000
Netsmart Revolving Facility [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread			4.75%
Debt instrument variable rate			4.75%
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.
[2]	Starting with the year ended December 31, 2017, additional amounts may be due within 125 days after year-end if Netsmart has “excess cash” as defined in the Netsmart Credit Agreement. For the year ended December 31, 2017, no additional amounts will be due as a result of this provision.

Summary of Future Debt Payment

Summary of Future Debt Payment Obligations (Detail) - USD ($) $ in Thousands		Mar. 31, 2018		Dec. 31, 2017
Debt Instrument [Line Items]
Total		$ 1,768,849		$ 1,620,066
Remainder of 2018		18,650
2,019		24,866
2,020		377,366
2,021		34,866
2,022		42,366
Thereafter		1,270,735
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total		345,000	[1]	$ 345,000
Remainder of 2018	[1]	0
2,019	[1]	0
2,020	[1]	345,000
2,021	[1]	0
2,022	[1]	0
Thereafter	[1]	0
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Total		400,000
Remainder of 2018		15,000
2,019		20,000
2,020		27,500
2,021		30,000
2,022		37,500
Thereafter		270,000
Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Total	[2]	478,099
Remainder of 2018	[2]	3,650
2,019	[2]	4,866
2,020	[2]	4,866
2,021	[2]	4,866
2,022	[2]	4,866
Thereafter	[2]	454,985
Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Total		167,000
Remainder of 2018		0
2,019		0
2,020		0
2,021		0
2,022		0
Thereafter		167,000
Revolving Facility [Member]
Debt Instrument [Line Items]
Total	[3]	378,750
Remainder of 2018	[3]	0
2,019	[3]	0
2,020	[3]	0
2,021	[3]	0
2,022	[3]	0
Thereafter	[3]	$ 378,750
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.
[2]	Starting with the year ended December 31, 2017, additional amounts may be due within 125 days after year-end if Netsmart has “excess cash” as defined in the Netsmart Credit Agreement. For the year ended December 31, 2017, no additional amounts will be due as a result of this provision.
[3]	Assumes no additional borrowings after March 31, 2018, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

Summary of Future Debt Paymen70

Summary of Future Debt Payment Obligations (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2018
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Maturity date	Jul. 1, 2020

Effective Tax Rates (Detail)

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Loss from continuing operations before income taxes	$ (35,844)	$ (8,393)
Income tax benefit (provision)	$ 2,914	$ (172)
Effective tax rate	8.10%	(2.00%)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Statutory tax rate	21.00%		35.00%
Provisional income tax benefit			$ 20.8
Tax benefit resulting from remeasurement deferred tax balance			26
Tax expense on accumulated foreign subsidiary earnings resulted from reduced federal rate			5.2
Cumulative operating income loss period considered	3 years
Unrecognized income tax benefits	$ 12.8		$ 12
ASU 2016-09 [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Tax expense on compensation cost	0.9	$ 1.4
Change in valuation allowance from offsetting release		(1.4)
Cumulative effect adjustment on accumulated deficit, gross		5.6
Recognition of previously unrecognized excess tax benefits		1.8
Valuation allowance recognized		$ 3.8
Valuation Allowance of Deferred Tax Assets [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance related to deferred tax assets from operating loss carryforwards	$ 10.7

Fair Value and Balance Sheet Lo

Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 25,913	$ 47,714
Derivative liability, fair value	26,446	47,777
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	503	1,136
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	0	0
Not Designated as Hedging Instrument [Member] | 1.25% Call Option [Member] | Other Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	25,410	46,578
Not Designated as Hedging Instrument [Member] | 1.25% Embedded Cash Conversion Option [Member] | Other Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 26,446	$ 47,777

Derivative Financial Instrume74

Derivative Financial Instruments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2018USD ($)Derivative	Mar. 31, 2018INR (₨)Derivative	Jun. 18, 2013USD ($)
1.25% Call Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts | Derivative	3	3
Derivative notional amount outstanding	$ 1,800,000	₨ 120,000,000
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	0
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	0
Unrealized derivatives gains (losses) included in other comprehensive (loss) income reclassified into income	$ 500,000
Estimated period of unrealized gains included in AOCI reclassified into income	12 months
Foreign Exchange Forward Contracts [Member] | Minimum [Member]
Derivative [Line Items]
Date of contracts mature	Apr. 30, 2018
Foreign Exchange Forward Contracts [Member] | Maximum [Member]
Derivative [Line Items]
Date of contracts mature	Jun. 30, 2018
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%
1.25% Notes Embedded Cash Conversion Option [Member] | Level 3 [Member] | Fair Value Measurements, Recurring [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option			$ 82,800,000

Derivatives Instruments Designa

Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ (78)	$ 1,873
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	189	178
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	144	137
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	$ 222	$ 210

Net Impact of Changes in Fair V

Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option - (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Derivative Instruments Gain Loss [Line Items]
Net (loss) gain included in other income, net	$ 163	$ (298)
1.25% Call Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net (loss) gain included in other income, net	(21,168)	17,605
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net (loss) gain included in other income, net	$ 21,331	$ (17,903)

Components of Accumulated Other

Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	$ 1,120,882
Other comprehensive income (loss) before reclassifications	65	$ (72,040)
Net losses (gains) reclassified from accumulated other comprehensive loss	(261)	(320)
Total other comprehensive loss	(196)	(72,360)
Balance at the end of the period	1,071,720
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(2,676)	(6,028)
Other comprehensive income (loss) before reclassifications	123	1,515
Net losses (gains) reclassified from accumulated other comprehensive loss	0	0
Total other comprehensive loss	123	1,515
Balance at the end of the period	(2,553)	(4,513)
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period		(56,420)
Other comprehensive income (loss) before reclassifications		(74,701)
Net losses (gains) reclassified from accumulated other comprehensive loss		0
Total other comprehensive loss		(74,701)
Balance at the end of the period		(131,121)
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	691	619
Other comprehensive income (loss) before reclassifications	(58)	1,146
Net losses (gains) reclassified from accumulated other comprehensive loss	(261)	(320)
Total other comprehensive loss	(319)	826
Balance at the end of the period	372	1,445
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(1,985)	(61,829)
Balance at the end of the period	$ (2,181)	$ (134,189)

Components of Accumulated Oth78

Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)			$ 60	$ 61
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 131	$ 445	$ 924	$ 402

Income Tax Effects Related to C

Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ 123	$ 1,515
Net change in unrealized gains (losses) on available for sale securities, Before-Tax Amount	0	(74,702)
Derivatives qualifying as cash flow hedges, net (loss) gain, Before-Tax Amount	(633)	1,348
Other comprehensive income (loss), Before-Tax Amount	(510)	(71,839)
Foreign currency translation adjustments, Tax Effect	0	0
Other comprehensive income (loss), Tax Effect	314	(521)
Foreign currency translation adjustments, Net	123	1,515
Other comprehensive income (loss), Net	(196)	(72,360)
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Available for sale securities, net loss arising during the period, Before-Tax Amount	0	(74,702)
Available for sale securities, net loss reclassified into income, Before-Tax Amount	0	0
Net change in unrealized gains (losses) on available for sale securities, Before-Tax Amount	0	(74,702)
Available for sale securities, net loss arising during the period, Tax Effect	0	1
Available for sale securities, net loss reclassified into income, Tax Effect	0	0
Net change in unrealized gains (losses) on available for sale securities, Tax Effect	0	1
Available for sale securities, net loss arising during the period, Net	0	(74,701)
Available for sale securities, net loss reclassified into income, Net	0	0
Net change in unrealized gains (losses) on available for sale securities, Net	0	(74,701)
Other comprehensive income (loss), Net		(74,701)
Derivatives Qualifying as Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net (loss) gain, Before-Tax Amount	(633)	1,348
Derivatives qualifying as cash flow hedges, net (loss) gain, Tax Effect	314	(522)
Derivatives qualifying as cash flow hedges, net (loss) gain, Net	(319)	826
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax Amount	(78)	1,873
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount	(555)	(525)
Derivatives qualifying as cash flow hedges, net (loss) gain, Before-Tax Amount	(633)	1,348
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect	20	(727)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	294	205
Derivatives qualifying as cash flow hedges, net (loss) gain, Tax Effect	314	(522)
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net	(58)	1,146
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net	(261)	(320)
Derivatives qualifying as cash flow hedges, net (loss) gain, Net	(319)	826
Other comprehensive income (loss), Net	$ (319)	$ 826

Income Tax Effects Related to80

Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Parenthetical) (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Revaluation of tax effects	$ 149

Commitments - Additional Inform

Commitments - Additional Information (Detail)	May 01, 2012USD ($)
Commitments And Contingencies Disclosure [Abstract]
Plaintiff sought amount for each alleged violation	$ 500

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2018USD ($)Offering
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Cash generated from discontinued operation	$ 4,300,000
EIS Business [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Number of product offerings acquired | Offering	2
Gain (Loss) on disposal of discontinued operation before tax	$ 0

Summary of Major Classes of Ass

Summary of Major Classes of Assets and Liabilities of Discontinued Operation (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Carrying amounts of major classes of assets included as part of discontinued operations:
Total assets attributable to discontinued operations	$ 4,945	$ 11,276
Carrying amounts of major classes of liabilities included as part of discontinued operations:
Total liabilities attributable to discontinued operations	14,276	21,358
EIS Business [Member]
Carrying amounts of major classes of assets included as part of discontinued operations:
Accounts receivable, net	2,265	8,196
Prepaid expenses and other current assets	2,680	3,080
Total assets attributable to discontinued operations	4,945	11,276
Carrying amounts of major classes of liabilities included as part of discontinued operations:
Accounts payable	104	114
Accrued expenses	6,150	5,599
Accrued compensation and benefits	8,022	7,728
Deferred revenue	0	7,241
Other classes of liabilities that are not major	0	676
Total liabilities attributable to discontinued operations	$ 14,276	$ 21,358

Summary of Major Classes of Lin

Summary of Major Classes of Line Items Constituting Income (Loss) of Discontinued Operation (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue:
Total revenue	$ 10,296
Cost of revenue:
Total cost of revenue	3,206
Gross profit	7,090
Selling, general and administrative expenses	0
Research and development	1,124
Income from discontinued operations before income taxes	5,966
Income tax provision	(1,551)
Income from discontinued operations, net of tax	4,415	$ 0
Software delivery, Support and Maintenance [Member]
Revenue:
Total revenue	9,804
Cost of revenue:
Total cost of revenue	2,463
Client services [Member]
Revenue:
Total revenue	492
Cost of revenue:
Total cost of revenue	$ 743

Business Segments - Additional

Business Segments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2018Segment
Segment Reporting Information [Line Items]
Number of reportable segments	3
Number of operating segments	10
Population Health [Member]
Segment Reporting Information [Line Items]
Number of operating segments	5

Revenues and Income from Operat

Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 513,926	$ 413,475
Gross Profit	220,975	178,652
Income (loss) from operations	(4,320)	11,263
Discontinued Operations [Member]
Segment Reporting Information [Line Items]
Revenue	(10,296)	0
Gross Profit	(7,090)	0
Income (loss) from operations	(5,966)	0
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	(1,948)	859
Gross Profit	(15,893)	(11,028)
Income (loss) from operations	(107,843)	(79,716)
Clinical and Financial Solutions [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	373,979	296,180
Gross Profit	154,286	119,261
Income (loss) from operations	70,742	53,582
Population Health [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	69,705	43,429
Gross Profit	53,371	35,845
Income (loss) from operations	36,434	28,468
Netsmart [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	82,486	73,007
Gross Profit	36,301	34,574
Income (loss) from operations	$ 2,313	$ 8,929

Supplemental Disclosures - Addi

Supplemental Disclosures - Additional Information (Detail)	Mar. 31, 2018LetterOfCredit
Netsmart [Member]
Schedule Of Supplemental Disclosures [Line Items]
Number of letter of credit maintained	2

Supplemental Disclosures (Detai

Supplemental Disclosures (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$ 135,003	$ 104,391	$ 155,839
Restricted cash	8,769		6,659
Total cash, cash equivalents and restricted cash	143,772	104,391	$ 162,498	$ 96,610
Supplemental non-cash information:
Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	12,149	10,962
Obligations incurred to purchase capitalized software or enter into capital leases	9,786	1,407
Contribution of assets in exchange for equity interest	$ 4,000	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - USD ($) $ in Millions	Apr. 27, 2018	Apr. 05, 2018	Apr. 02, 2018
Health Grid [Member]
Subsequent Event [Line Items]
Purchase price in cash	$ 60
Health Grid [Member] | Maximum [Member]
Subsequent Event [Line Items]
Potential earnout payments	$ 50
Membership Interest Purchase Agreement
Subsequent Event [Line Items]
Business combination, aggregate consideration		$ 167.5
Date of acquisition		Apr. 5, 2018
Escrow deposited		$ 2.5
One Content Business [Member]
Subsequent Event [Line Items]
Date of divestiture			Apr. 2, 2018
Business combination, aggregate consideration			$ 260